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1 Haemocomplettan® P alone or in combination 
with Fibrogammin® P in acquired 
hypofibrinogenemia 
1.1 Background 
Haemostasis is a complex process employing a multitude of cells, blood co-
agulation factors (clotting factors), co-factors, and regulators (activators and 
inhibitors) following the damage of a blood vessel in order to stop bleeding. 
Fibrinogen – coagulation factor I – is activated by thrombin which leads to 
the conversion to fibrin. In addition, thrombin converts fibrin-stabilising 
factor – coagulation factor XIII – into its active form XIIIa1. Fibrin mono-
mers aggregate to fibrin polymers and are being cross-linked and hence stabi-
lised by factor XIIIa. Therefore, both factors I and XIII are essential in 
building a fibrin clot.  
Clotting factor deficiencies may be inherited through mutations of genes en-
coding the respective coagulation factor. The gene for fibrinogen is located 
on chromosome 4, that of  factor XIII on both chromosomes 6 and 1. Such 
deficiencies occur rarely - estimations range from 1 per 500,000 to 1 per 
2,000,000 individuals [1]. More frequently, a lack of fibrinogen is acquired 
through impaired synthesis, increased loss, or increased consumption caused 
by various underlying clinical conditions, such as disseminated intravascular 
coagulopathy (DIC), hepatic insufficiency, life-threatening bleeding, dilu-
tional coagulopathy, severe trauma, or long-term corticosteroid therapy [2]. 
Similarly, a lack of factor XIII may be acquired through major surgery, DIC, 
sepsis, chronic inflammatory bowel diseases, Purpura Schönlein-Hennoch, 
hepatic insufficiency, and systematic haematologic diseases. [3].   
1.2 Haemocomplettan® P2 
1.2.1 Fibrinogen 
The normal plasma concentration of fibrinogen ranges from 2.0 to 4.5 g/L 
(gram per litre). Its plasma half-life3 is 3 to 5 days [4]. As an acute phase pro-
tein its concentration is subject to variability and may be increased for differ-
ent reasons, such as inflammation, tumors, pregnancy, or after surgery. In 
massive haemorrhage, crystalloids and colloids are being substituted, leading 
to the development of dilutional coagulopathy with a drop of fibrinogen be-
low a critical level [5, 6]. This critical level, however, is highly disputed. In 
several guidelines, a fibrinogen level of less than 1.0 g/L is considered as a 
threshold for substitution of blood products [6-10]. The German Medical 
Association defined an additional threshold of <1.5 g/L in severe haemor-
                                                               
1 a = activated 
2 P = pasteurised 
3 half-life = the time it takes for a substance to decrease by half 
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rhage [10]. The Task Force for Coagulation of the Austrian Society of Anes-
thesiology, Resuscitation and Intensive Care Medicine (ÖGARI) “strongly 
recommends” to maintain a fibrinogen level of 1.5 to 2 g/L in trauma-related 
massive bleeding [11]. Recently, one study suggested that women with a fi-
brinogen concentration of less than 2 g/L may already be at high risk of se-
vere bleeding in post-partum haemorrhage [12].  
Depending on the urgency in massive haemorrhage, fibrinogen might be 
substituted either preventively or according to plasma fibrinogen levels as 
determined by conventional coagulation tests, such as the Clauss assay, or 
ROTEM® rotational thrombelastometry, a recently developed point-of-care 
device. The rationale behind this approach is the fact that in massive haem-
orrhage depletion of fibrinogen occurs early during progression of coagulopa-
thy [5, 6]. 
1.2.2 Sources of fibrinogen 
Fibrinogen may be substituted as fresh frozen plasma (FFP), Octaplas® SD4, 
cryoprecipitate, or fibrinogen concentrate.  
FFP 
FFP is derived from whole blood or by plasmapheresis from a single donor’s 
blood after removing blood cells. It is stored at minus 30°C5 and has to be 
thawed at 37°C before it can be used, which takes at least 30 minutes. One 
unit of FFP contains all coagulation factors, including 2 to 5 g/L fibrinogen, 
dissolved in about 150 to 400 millilitre (mL) of plasma. The recommended 
dose is 10 to 15 (millilitre per kilogram (mL/kg) body weight but depends 
upon the individual blood loss. AB0 blood group typing is necessary before 
FFP can be orderd and transfused to a patient [5]. 
Octaplas® SD 
Octaplas® SD is solvent-detergent treated human plasma derived from mul-
tiple donors and is used for the same indications and at the same dosage as 
FFP. Similar to FFP, it has to be thawed and ABO-blood group compatibil-
ity has to be tested before administration. The clotting factor content of Oc-
taplas® SD is lower than that of FFP due to the virus inactivation process. 
One 200 mL bag of Octaplas® SD contains 9 to 14 g human plasma proteins. 
The specific amount of fibrinogen, however, depends on the fibrinogen con-
centration of the respective donor(s) [13]. 
Cryoprecipitate 
Cryoprecipitate is derived from FFP, when thawed at 1°C to 6°C. It can be re-
frozen but should be used within 12 months. One unit contains 100 to 350 
mg fibrinogen (6.7 to 23 g/L), FXIII, FVIII, von Willebrand factor, fibronec-
tion, albumin, immunglobulin (Ig) G and IgM, dissolved in typically 15 mL 
                                                               
4 SD = solvent detergent  
5 C = Celsius 
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of plasma. It has to be thawed before administration as well but it can be 
thawed more quickly than FFP because of the smaller volume. The dose is 
calculated individually and depends upon the current fibrinogen level, the 
desired increase in fibrinogen level, and the plasma volume of the respective 
patient [5, 14, 15]. Although cryoprecipitate is not very frequently used in 
Europe (but is common in Northern America), it can be easily prepared by 
most blood banks.  
Fibrinogen concentrate (Haemocomplettan® P) 
Fibrinogen concentrates are produced from pooled human plasma (derived 
from selected donors) under highly controlled and standardised conditions 
by pharmaceutical companies with high experience in the production of 
blood products. Due to sophisticated virus inactivation procedures the risk of 
pathogen transmission is low [16]. The products come as lyophilized dry 
powder with an exactly defined amount of purified fibrinogen (1 or 2 g per 
vial). Before administration (as a slow injection) it has to be dissolved in 50 
to 100 mL of water for injection, resulting in a fibrinogen concentration of 20 
g/L [13]. The low volume does not lead to volume overload and allows the 
administration of high amounts of fibrinogen within a short time.  
1.2.3 Indication 
In Austria Haemocomplettan® P is licensed for the prevention of haemor-
rhagic diathesis in congenital afibrinogenemia, hypofibrinogenemia, and 
dysfibringoenemia as well as for acquired hypofibrinogenemia due to im-
paired synthesis, increased consumption, or increased loss of fibrinogen. 
First approval was granted in 1994 with renewal of approval in 2004 [13].  
1.2.4 Regulatory Status 
The World Federation of Hemophilia provides an overview of clotting factor 
concentrates available throughout the world [17]. The fibrinogen concen-
trates Haemocomplettan® P and RiaSTAP™ are being manufactured by CSL 
Behring GmbH, Marburg, Germany [17]. The manufacturers and its prede-
cessors have been producing and marketing fibrinogen for the use in con-
genital and acquired fibrinogen deficiencies since the mid 1950s. In 1977, 
however, the United States Food and Drug Administration (FDA) revoked 
all licenses for fibrinogen concentrates – affecting several companies, includ-
ing CSL Behring - due to the risk of hepatitis transmission and lack of evi-
dence regarding the effectiveness of fibrinogen [18, 19]. By contrast, in Japan 
fibrinogen concentrate was administered for the treatment of obstetric bleed-
ing until 1988, resulting in about 10,000 cases of hepatitis C infection [19]. 
Since then the manufacturing process has been improved, particularly with 
regard to the pasteurisation step, when plasma is being heated at 60°C for 20 
hours in order to inactivate a number of viruses, such as hepatitis C virus and 
HIV [18].  
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The trade name Haemocomplettan® P was introduced by CSL Behring in 
1985. Fibrinogen concentrate is licensed as Haemocomplettan® P in some 
European countries, such as Austria, Germany, Switzerland, Portugal and the 
Netherlands. Moreover, it is available on a patient-name basis in 11 Euro-
pean countries, including Iceland, Norway, Sweden, Finland, Denmark, 
United Kingdom, Belgium, France, Spain, Italy and Greece [20]. Licensures 
were granted nationally, however, an approval by the European Medicines 
Agency (EMEA) does not exist. In addition, fibrinogen concentrate is li-
censed as Clottagen in France, Fibrinogen HT in Japan, and FIBRORAAS in 
China. Furthermore, fibrinogen concentrate has been licensed as RiaSTAP™ 
in the United States since January 2009 [17].  
1.2.5 Estimated performance and costs 
An assessment6 revealed that between January 2009 and June 2009 the con-
sumption of Haemocomplettan® P varied remarkably within selected Aus-
trian hospitals, including the General Hospital Vienna and St. Anna Chil-
dren’s Hospital, University Hospital Graz, University Hospital Innsbruck, 
General Hospital Salzburg, General Hospital Klagenfurt, Hospitals Wels and 
Grieskirchen, and Hospital St. Pölten. During this time period the highest 
consumption in one of the hospitals was 146 vials of Haemocomplettan® P, 
containing one gram of fibrinogen, per 100 beds, whereas in all other hospi-
tals it ranged from 26 to 69 vials per 100 beds (personal communication).  
Within all public hospitals in one Austrian province, the consumption of 
Haemocomplettan® P has been increasing steadily since 2001. It rose more 
than seven-fold from 484 gram (g) in 2001 –with a short decline in 2002 – to 
3,576 g in 2008. Similarly, the costs increased more than 24-fold from €7 
36,036 in 2001 to € 878,737 in 2008. In the largest of these hospitals, which is 
a University Hospital, 2,456 g of Haemocomplettan® P were used in 20088, 
59% and 37% of which were administered in the operating theatre and the in-
tensive care unit, respectively. The remaining 4% were given to patients on 
the ward and in the outpatient clinic. In comparison, 322 g of Haemocom-
plettan® P were used in this hospital in 20015 (personal communication). 
A University Hospital in another Austrian province, shows the same trend 
regarding Haemocomplettan® P consumption. It increased constantly from 
797 g in 20019 – with a short decline in 2003 – to 3,501 g in 2008 and is ex-
pected to reach 4,132 g in 20096. Since in Austria one vial of Haemocomplet-
tan® P, containing one gram of fibrinogen, is € 352.4 [13], the costs for the 
                                                               
6 In this assessment the hospital with the highest consumption of Haemocomplettan® 
P is known and is compared anonymously to the other hospitals. 
7 € = Euro 
8 According to the studies identified in our review with the amount of fibrinogen 
concentrate administered being between 2 to 8 gram, between approximately 300 
and 1200 patients must have been treated in 2008. In comparison, between 40 and 
160 patients must have been treated in 2001. 
9 According to the studies identified in our review with the amount of fibrinogen 
concentrate administered being between 2 to 8 gram, between approximately 100 
and 400 patients must have been treated in 2001. However, this figure is estimated 
to increase to about 500 to 2000 patients in 2009. 
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substitution of fibrinogen are estimated to reach € 1,456,117 in 2009 - a more 
than 5-fold increase since 2001. 
In comparison, the price for FFP ranges from € 73.45 to € 81.86 (personal 
communication). Furthermore, one bag of 200ml Octaplas® SD human 
plasma solution for intravenous infusion is between € 87.1 and € 91.05, de-
pending on the ABO-blood group [13]. 
1.3 Fibrogammin® P 
1.3.1 Factor XIII 
The normal plasma concentration of factor XIII is 0.02 g/L [4]. Effective 
haemostasis may be achieved with as little as 1% of enzymatic activity [21]. 
In addititon, its half-life is 9 to 10 days [4]. There are different assays in use 
for determining factor XIII activity [22] and usually results from the labora-
tory are available within one week. Factor XIII concentration is expressed as 
units per millilitre (U/mL), whereby 1 U/mL equals 100% factor XIII activity 
of a normal control plasma. 
In severe haemorrhage, clotting factor XIII might be administered preven-
tively without prior determining its plasma concentration because this is not 
part of routine coagulation tests [3].  
1.3.2 Sources of factor XIII 
Factor XIII may be substituted as FFP, Octaplas® SD, cryoprecipitate, or fac-
tor XIII concentrate.  
FFP/ Octaplas® SD/ Cryoprecipitate 
A detailed description of FFP, Octaplas® SD, and cryoprecipitate is available 
at 1.2.2. The specific amount of factor XIII in these blood products, however, 
depends on the factor XIII activity of the respective donor(s).  
Factor XIII concentrate (Fibrogammin® P) 
Factor XIII concentrate is produced from pooled human plasma (derived 
from selected donors) under highly controlled and standardised conditions 
by pharmaceutical companies with high experience in the production of 
blood products. Due to sophisticated virus inactivation procedures the risk of 
pathogen transmission is low [16]. The product comes as lyophilised dry 
powder in vials containing either 250 units (U) or 1,250 U of factor XIII. The 
content of these 250 U and 1,250 U vials is being dissolved in 4 mL and 20 
mL of water for injection, respectively, prior to administration as a slow in-
jection. The recommended dosage is at least 15 to 20 U per kg body weight 
[13]. 
normal plasma 
concentration 0.02 g/L, 
1% of normal enzymatic 
activity is sufficient for 
hemostasis 
multiple donors, 
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content 
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1.3.3 Indication 
In Austria Fibrogammin® P is licensed for the treatment of patients with 
congenital factor XIII deficiency and resulting haemorrhagic diathesis, 
haemorrhage, and wound healing disorders. In addition, it is approved for 
the treatment of patients with hemorrhagic diathesis due to acquired factor 
XIII deficiency, for supportive care of wound healing disorders, and to im-
prove consolidation of bone fractures. First approval was granted in 2000 
with renewal of approval in 2005 [13].  
1.3.4 Regulatory Status 
Factor XIII concentrate is manufactured by CSL Behring GmbH, Marburg, 
Germany and is licensed as Fibrogammin® P in Austria and several other 
countries within the European Union as well as in Japan. However, it is not 
available in the United States, where factor XIII deficiencies are being 
treated with FFP and cryoprecipitate [2]. 
1.3.5 Estimated performance and costs 
Among all public hospitals in one Austrian province, the consumption of Fi-
brogammin® P varied consideraby between 2001 and 2008. It ranged from 
69,000 U to 91,250 U between 2001 and 2006, increased steeply to 139,250 U 
in 2007 and plummeted to 63,750 U in 2008. Costs for Fibrogammin® P 
ranged from € 13,168 to € 66,026 during this time period (personal commu-
nication). 
In a University Hospital in another Austrian province the consumption of 
Fibrogammin® P rose from 18,250 U in 2002 - with a short decrease in 2003 - 
to 279,500 U in 2008 and is estimated to reach 354,000 U in 2009, equalling a 
more than 19-fold increase since 2002. One vial of Fibrogammin® P, contain-
ing 250 U of fibrin-stabilising factor, is € 154.6 [13]. One vial of 1,250 U is € 
648.05. Hence, the costs for the substitution of fibrin-stabilising factor are es-
timated to reach between € 183,528 and € 218,914 in 2009 – a more than 19-
fold increase since 2002 (personal communication). 
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2 Guidelines for the transfusion of blood products 
In Austria, national transfusion guidelines do not exist, which leads to a con-
siderable variability in the substitution of blood products among different 
institutions. 
Recommendations for coagulation management in trauma-related massive 
bleeding have been issued by the Task Force for Coagulation of the ÖGARI 
[11]. These include recommendations on the substititution of fibrinogen 
concentrate and factor XIII concentrate in this specific setting. According to 
these guidelines, the substitution of fibrinogen concentrate should be guided 
by ROTEM® rotational thrombelastometry or, if this is not achievable, a fi-
brinogen level of 1.5 to 2 g/L should be maintained. In addition, factor XIII 
concentrate should be administered empirically without prior measurement 
of factor XIII activity at a dosage of 30 U per kg body weight in low clot 
strength as estimated by ROTEM® analysis. 
Likewise, local guidelines for one University Hospital in Austria have been 
launched by two authors who are also part of the Task Force for Coagulation 
of the ÖGARI [23]. These guidelines contain similar recommendations for 
the administration of fibrinogen concentrate. The settings, however, have 
been extended to perioperative use, severly ill patients, and critically ill in-
tensive care unit patients. The substitution of factor XIII concentrate is not 
accounted for in these guidelines. 
Further guidelines for the transfusion of blood products are availabale from 
Canada, Great Britain, Germany, and a European Expert Group [6-10]. Nev-
ertheless, these recommendations are subject to substantial variability re-
garding indications, settings, cut-off levels, and dosages of different blood 
products. The German Medical Association issued guidelines for the substi-
tution of fibrinogen in acquired fibrinogen deficiency [10]. According to 
these guidelines, the threshold for the occurrence of spontaneous haemor-
rhage is a fibrinogen level of < 1 g/L. This threshold, however,  increases to 
< 1.5 g/L in severe haemorrhage. Furthermore, it is emphasised that the fi-
brinogen level should be determined specifically. The fibrinogen dosage can 
be calculated and depends on the desired increase in fibrinogen level and the 
plasma volume of the respective patient, which in turn depends on the body 
weight. The required dose for adults is 3 to 6 g. After fibrinogen replacement, 
the fibrinogen plasma level should be controlled and should be above the 
critical level of about < 1 g/L [10]. The multidisciplinary Task Force for Ad-
vanced Bleeding Care in Trauma developed European guidelines for the 
management of haemorrhage in trauma patients [9]. According to these, fi-
brinogen should be subtituted in severe bleeding with a plasma fibrinogen 
level of < 1g/L. The recommended dosage is 3 to 4 g of fibrinogen concen-
trate or 50 mg/kg body weight of cryoprecipitate initially, followed by further 
administration according to the fibrinogen level as determined by laboratory 
tests. 
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Studies have been conducted assessing the appropriateness of blood product 
substitution, particularly of FFP and cryoprecipitate [14, 24-26]. Overall, 
there is lack of evidence from randomised controlled trials confirming the ef-
fectiveness of FFP infusion in various underlying clinical conditions, such as 
liver diseases, cardiovascular diseases, or DIC, and current guidelines are 
mainly based on observational studies [24]. A number of audits showed that 
in many cases the administration of cryoprecipitate and other blood products 
was inadequate. In a tertiary care medical centre in Boston, 24% (12/51) of 
patients received cryoprecipitate for the wrong indication over a period of 19 
weeks [14]. In 25 hospitals in Canada about one third (34%) of cryoprecipi-
tate transfusions during eight weeks were considered inappropriate. Fur-
thermore, another 42% of cryoprecipitate transfusions may have been done 
for wrong indications but this could not be established [26]. In New South 
Wales the percentage of cryoprecipitate substitutions assessed as having been 
inappropriate was 62% over a period of 8 months. In addition, 33% of plate-
lets and 37% of FFP transfusions were considered inadequate [25]. 
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3 Technical comparison of Clauss fibrinogen assay 
and ROTEM® rotational thrombelastometry 
The Clauss method has been employed for determining plasma fibrinogen 
concentrations since 1957 [27]. As it has been suggested to be the most reli-
able of the laboratory methods used for determining the fibrinogen level [28], 
we considered it the “gold standard”. However, there is a variety of labora-
tory tests available for quantifying the fibrinogen level [28, 29]. Rotational 
thrombelastometry ROTEM® evolved from thrombelastographic methods 
first described by Hartert in 1948 [30, 31] and was launched in 1995 [32]. Ta-
ble 3-1 shows a comparison of Clauss functional fibrinogen assay and the 
ROTEM® rotational thrombelastometry method. 
Table 3-1: Clauss fibrinogen assay versus ROTEM® method for estimating fibrinogen activity 
 Clauss fibrinogen assay ROTEM® [33] 
Introduced 1957 [27]; considered as “gold standard”, ref-erence test 
1995 [32]; based on thrombelastography intro-
duced by Hartert in 1948 [30, 31] 
Setting laboratory point-of-care 
Sample cell-free citrated plasma sample [27] citrated whole-blood sample [34] 
Duration 30-50 min.
1 [35] including centrifugation and 
sample transport 
10-30 min. [30, 35-37], depends on parameter as-
sessed; FIBTEM2: 10 min. [35] 
Type of assay quantitative assay qualitative test 
Unit g/L3 
mm4 
sec5 
°6 
% of MCF7 
MCF, CA8 
 
Analyser/ reagent/ 
assay protocol 
various analysers (including machines), re-
agents and assay protocols [28, 38] dedicated device and reagents [28] 
Calibration against commercial reference standards  [28, 38] 
against reference individuals [36, 37] or plasma 
quality control standards provided by manufac-
turer [39]  
Establishing refer-
ence ranges should be done in each laboratory [28] should be done in each laboratory [37] 
Inter-centre/ ana-
lyser variability for 
reference prepara-
tions/ reference 
ranges 
no significant differences in reference prepa-
rations between centres or analysers [38] comparable reference ranges between centres [37]
Repeatability 
(within-run impreci-
sion) 
- coefficient of variation depends upon individual test and parameter, between 2% and 13% [37] 
Costs per single 
analysis 
€9 14.43 (Clinical Department for Medical 
and Chemical Laboraroy Diagnostics, Medi-
cal University of Vienna) 
£10 4 [40]/ €9 5 [41]  
_____________________________________________________________________________________ 
1 min = minutes 
2 FIBTEM = one test of ROTEM® 
3 g/L = gram per litre 
4 mm = millimetre 
5 sec = seconds 
6 ° = grade 
7 MCF = maximum clot firmness 
8 CA = clot amplitude 
9 € = Euro  
10 £ = United Kingdom Pounds 
Clauss method since 
1957, ROTEM® method 
since 1995 
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The Clauss fibrinogen assay is conducted in the laboratory at 37°C [27]. For 
measuring the fibrinogen concentration with the Clauss method blood is 
drawn into tubes filled with trisodium citrate and centrifuged to obtain plate-
let poor plasma. Following dilution of plasma, thrombin in high concentra-
tions is added and the clotting time is measured. This time is converted into 
the level of functional fibrinogen (in g/L) using a normogram obtained from 
a reference sample [27, 28]. Including the centrifugation procedure it takes 
about 30 minutes to run this assay [35]. The Clauss method may be per-
formed manually or by automated coagulometers [28]. A variety of analysers 
(including machines), reagents and assay protocols is available and in use 
[38]. Calibration is done against commercial reference standards, national, or 
international standards [28, 38] and should be done daily. An evaluation of 
commercial reference preparations in the United Kingdom found no signifi-
cant differences in the variability of reference standards between centres or 
analysers [38]. As necessary for nearly all coagulation assays, it has been rec-
ommended to establish reference ranges for each laboratory by testing at least 
40 healthy males and females of various age groups [28].  According to the 
Department for Medical and Chemical Laboratory Diagnostics of the Medi-
cal University of Vienna, the cost for a single analysis is about €14.34. 
ROTEM® rotational thrombelastometry is marketed by Pentapharm GmbH, 
Munich, Germany [33]. It employs six different tests for the measurement of 
coagulation disorders, including INTEM, EXTEM, FIBTEM, HEPTEM, 
APTEM, and NATEM that assess distinct parameters of both the extrinsic 
and intrinsic pathway of the coagulation and therefore require various activa-
tors and inhibitors [30, 33, 42]. The analyser consists of four independent, 
temperature-controlled measurement channels [37, 42]. For determining the 
fibrinogen-dependent component of blood coagulation, whole blood drawn 
into trisodium citrate is used. Because whole blood samples are employed in 
this method, results depend on the hematocrit level. With the FIBTEM 
method, the maximum clot firmness (MCF) and the clot amplitude after 5 or 
10 minutes runtime are considered to best estimate fibrinogen activity. RO-
TEM® is a point-of-care device yielding results within 10 to 30 minutes [30, 
35-37], depending on the parameter assessed [35]. Calibration is done against 
reference individuals [36, 37] or plasma quality control standards provided 
by the manufacturer [39]. It should be done daily and takes about 15 minutes 
[35]. A multi-centre investigation on reference ranges for ROTEM® found no 
differences between centres in Austria, Germany and France. However, it has 
been recommended to establish reference ranges in each laboratory [37]. 
Moreover, the repeatability (within-run imprecision) seems to depend on the 
parameter assessed and has been shown coefficients of variation ranging from 
2% to 13% [37]. In the FIBTEM test of ROTEM® the single contribution of 
fibrinogen to the clot firmness is assessed by inhibiting platelets, allowing in-
ferences about the fibrinogen concentration and function [34]. The cost for a 
single analysis is about  €5 [41].  
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measures level of 
functional fibrinogen in 
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30 minutes 
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4 Literature search and selection 
4.1 PICO-Question 
i ) Efficacy and safety of Haemocomplettan® P alone or in combination 
with Fibrogammin® P in acquired hypofibrinogenemia in children 
and adults compared to FFP/ Octaplas® SD/ Cryoprecipitate. 
ii ) Accuracy of ROTEM® point-of-care testing compared to standard 
laboratory tests for determining the need for the transfusion of 
blood products in acquired hypofibrinogenemia. 
4.2 Inclusion Criteria 
Inclusion criteria for relevant studies are outlined in table 4.2-1. 
Table 4.2-1: Inclusion Criteria 
Population children and adults with acquired hypofibrinogenemia/ fibrinogen defi-
ciency/ fibrinogen defect 
Interven-
tion 
Question i)  
 Haemocomplettan® P 
 Fibrogammin® P 
Question ii) 
 ROTEM® point-of-care testing  
Control Question i) 
 Fresh Frozen Plasma (FFP) 
 Octaplas® SD 
 Cryoprecipitate 
Question ii) 
 standard laboratory haematosis tests 
 Clauss assay 
Outcomes  Question i) 
 bleeding/ haemorrhage  
 necessity of substitution of blood products other than clotting 
factors I and XIII 
 reduction in the use of blood products other than clotting fac-
tors I and XIII, particularly FFP/ Octaplas® SD 
Question ii) 
 correlation ROTEM®/ standard laboratory tests 
Study de-
sign 
Question i) 
 for efficacy: all prospective, controlled studies 
 for safety: all studies 
PICO-questions 
Haemocomplettan® P alone or in combination with Fibrogammin® P in acquired hypofibrinogenemia 
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4.3 Search strategy 
We conducted a systematic literature search in the following databases on 29 
October 2009:  
 Medline via Ovid 
 Embase  
 INAHTA – CRD  (DARE -NHS EED- HTA) 
 The Cochrane Library 
In addition, we searched for assessments on the following websites:  
 WHO Health Evidence Network  
(http://www.euro.who.int/HEN) 
 Canadian Agency for Drugs and Technologies in Health 
(http://www.cadth.ca/index.php/en/home) 
 National Coordinating Centre for Health Technology Assessment 
(http://www.hta.nhsweb.nhs.uk/)  
 NHS Institute for Health and Clinical Excellence 
(http://guidance.nice.org.uk/) 
We limited the literature search to articles published in English and German 
between 1985 and 2009. After deduplication the search yielded 531 results. 
Furthermore, we conducted a hand search, adding up to 827 references after 
deduplication. The detailed search strategy is available on request from the 
LBI-HTA.   
We requested information regarding Haemocomplettan® P and Fibro-
gammin® P from CSL Behring, Germany. In addition, we asked the Austrian 
Agency for Health and Food Safety (AGES) PharmMed for information on 
the national licensure of Haemocomplettan® P and Fibrogammin® P. More-
over, we contacted Pentapharm, Germany for information on the ROTEM 
system but did not receive a response. We contacted several hospitals in Aus-
tria and Germany requesting guidelines for haemostasis management in the 
perioperative setting.   
 
systematic literature 
search in several 
databases 
additional search on 
websites 
limits: English and 
German language, 1985 
to 2009 
827 references 
 
contacting of industry 
and Austrian approval 
agency 
Literature search and selection 
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4.4 Literature Selection 
Overall, the literature search yielded 827 results. Two reviewers independ-
ently screened, assessed and included the abstracts. In cases of disagreement, 
we achieved consensus either through discussion or by involving a third per-
son. The selection process is displayed in figure 4.4-1:  
 
Figure 4.4-1: Selection process (PRISMA Flow Diagram)  
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5 Evaluating the quality of studies 
Two reviewers independently assessed the internal validity of the studies. In 
cases of disagreement, we achieved consensus either through discussion or by 
involving a third person. A detailed description of the criteria for assessing 
the internal validity of individual studies can be found in the Internal Man-
ual of the LBI-HTA [43]. 
6 Extraction of data 
One person extracted the data and a second person reviewed the extracted 
data regarding completeness and accurateness. 
6.1 Study results 
Overall, we found four studies concerning the efficacy of Haemocomplettan® 
P [44-47], nine studies assessing the safety of Haemocomplettan® P [45-54], 
and one trial regarding Fibrogammin® P [55]. In addition, we identified 
three studies comparing ROTEM® rotational thrombelastometry and stan-
dard laboratory haemostasis tests [32, 35, 36]. Moreover, two studies assessed 
the consumption of blood products before and after ROTEM® implementa-
tion [40, 41].  
6.1.1 Haemocomplettan® P 
Efficacy 
Four comparative studies could be identified, two of which were prospective, 
randomised controlled trials and the remaining two were cohort studies [44-
47]. The four studies are summarised in table 6.1.1-1 and table 6.1.1-2. One of 
the cohort studies consisted of a prospective study group and a historical 
control, the other one comprised a prospective intervention group and both a 
prospective and a retrospective control group. Overall, 74 patients – 37 in the 
intervention and 37 in the control groups - were included in the studies.  
 
independently by 2 
reviewers 
overall 17 studies 
included 
4 studies, 74 patients, 
37 each in intervention 
and control arm 
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Table 6.1.1-1: Studies concerning the efficacy of Haemocomplettan® P in acquired hypofibrinogenemia 
 
author, year, 
reference no. 
funding/ 
setting aim 
study design/ 
study population intervention primary/ secondary outcomes 
Rahe-Meyer N 
et al., 2009  
[46] 
CSL Behring, Mar-
burg, Germany/  
Hannover Medical 
School, Germany 
assess the efficacy of infusion of 
fibrinogen concentrate in pa-
tients pts.1 undergoing elective 
TAAA2 surgery 
comparative study with histori-
cal control; 
I3: prospective n4=6 vs.5  
C6: retrospective n=12 
I: administration of Haemocom-
plettan® P  prior to standard trans-
fusion algorithm; 
trigger: intraoperative blood loss 
between 60 and 250g7;  
mean amount of fibrinogen sub-
stituted 7.8±2.7g 
 
C: standard transfusion algorithm 
(PC8 and/or FFP9, if needed) 
primary: transfusion of allogeneic blood products 
intraoperatively and during 24h10 postopera-
tively; no transfusion triggers pre-defined; 
secondary: 
number of pts. without any transfusion 24h post-
operatively; 24h postoperative drainage volume 
Rahe-Meyer N 
et al., 2009 [45] 
CSL Behring, Mar-
burg, Germany/  
Hannover Medical 
School, Germany 
compare haemostatic effects of 
conventional transfusion man-
agement and  fibrinogen concen-
trate administration in pts. un-
dergoing AV-AA11 
comparative, prospective study; 
no randomisation, no blinding;  
I: n=10 vs. C: n=5  
I: administration of Haemocom-
plettan® prior to standard transfu-
sion algorithm; 
trigger: intraoperative blood loss 
between 60 and 250g;   
mean amount of fibrinogen sub-
stituted 7.5g (0.7g SD12) 
 
C: standard transfusion algorithm 
(PC and/or FFP, if needed) 
primary: transfusion of allogeneic blood products 
after CPB13 during 24h postoperatively;  no trans-
fusion triggers predefined; 
secondary: 
24h postoperative drainage 
volume 
Karlsson M et 
al., 2009 [47] 
CSL Behring, Mar-
burg, Germany; 
Sahlgrenska Univer-
sity Hospital, Swe-
den; 
Swedish Heart & 
Lung Foundation/  
Sahlgrenska Univer-
sity Hospital, Sweden 
assess the feasibility of prophy-
lactic infusion of fibrinogen con-
centrate to CABG14 pts. 
prospective, randomised con-
trolled phase I-II study;  
I: n=10 vs. C: n=10 
 
 
 
I: pre-operative infusion of 2g fi-
brinogen concentrate 
 
C: no infusion before surgery 
primary: i) clinical adverse events: signs of central 
or peripheral thrombembolism, respiratory or cir-
culatory failure; allergic reactions; 
ii) graft occlusion assessed by CT15 3-4 days after 
surgery; 
secondary: i) postoperative bleeding (total 
amount of chest tube drainage after closure of 
the sternum and during the first 12 postoperative 
hours); 
ii) transfusion of blood products according to pre-
defined transfusion triggers; 
iii) haemoglobin concentration 24h after surgery; 
iv) effects of fibrinogen infusion on global 
haemostasis 2h and 24h after surgery by assessing 
clot formation via ROTEM® 
Extraction of data 
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Fenger-
Eriksen C et 
al., 2009 
[44]  
CSL Behring, Marburg, 
Germany;  
University of Aarhus 
Research Foundation; 
A. P. Mo/ller and Hustru 
Chastine Mc Kinney 
Mo/llers Foundation/ 
Department of Urology, 
Aarhus University Hos-
pital, Skejby, Denmark 
investigate the likelihood of co-
agulopathy after haemodilution 
with HES16 130/0.4 and evaluate 
hemostatic effect of concen-
trated fibrinogen infusion in pts. 
undergoing radical cystectomy 
prospective, double-blind, ran-
domised, placebo-controlled 
study;  
I: n=11 vs. C: n=10;  
overall, 20 pts. were evaluated, 
10 each in the I and C; no ITT17 
analysis  
I: IV18 administration of  45mg/kg19 
Haemocomplettan®; 
trigger: 30% reduction in hema-
tocrit level after dilution with 
HES20 130/0.4 
 
C: IV administration of placebo = 
2.25mg/kg  isotonic saline 0.9%  
primary: MCF21 as determined by  ROTEM®; 
secondary: i) other thrombelastometric variables; 
ii) platelet function;  
iii) thrombin generation;  
iv) bleeding; 
v) requirement for peri- and postoperative blood 
product transfusion according to pre-defined 
transfusion triggers 
_______________________________________________________________________________________ 
1 pts = patients 
2 TAAA = thoracoabdominal aortic aneurysma 
3 I = intervention group 
4 n = number 
5 vs = versus 
6 C = control group 
7 g = gram 
8 PC = platelet concentrate 
9 FFP = fresh frozen plasma 
10 h = hours 
11AV-AA = aortic valve operation and ascending aorta replacement 
12 SD = standard deviation 
13 CPB = cardio-pulmonary bypass 
14 CABG = coronary artery bypass graft 
15 CT = computed tomography 
16 HES = hydroxyethyl starch 
17 ITT = intention-to-treat  
18 IV = intravenous 
19 mg/kg = milligram per kilogram 
20 HES = hydroxyethyl starch  
21 MCF = maximum clot firmness 
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Table 6.1.1-2: Results of efficacy studies of Haemocomplettan® P in acquired hypofibrinogenemia  
Results author, year, refer-
ence no. 
primary outcomes intervention control p-value secondary outcomes intervention control  p-value 
Rahe-Meyer N et al., 
2009 [46] 
total concentrates (u1) 
RBC2 (u) 
FFP3 (u) 
PC4 (u) 
2.5±4.3 
1.0 
1.0 
0.5 
16.4±4.8  
4.1 
9.1 
3.2 
<0.05 
<0.05 
<0.05 
<0.05 
no transfusion 
drainage volume (mL5) 
4 (67%) 
449±182 
0 
1093±594 
<0.05 
<0.05 
 
Rahe-Meyer N et al., 
2009 [45] 
total concentrates (u)  
RBC (u) 
FFP (u) 
PC (u) 
0.7±1.5 
0.5±1.1 
0.2±0.6 
0.0 
8.2±2.3 
2.4±1.1 
4.2±1.1 
1.6±0.9 
<0.05 
<0.05 
<0.05 
<0.05 
drainage volume (mL) 366±199 716±219 <0.05 
 
i) postoperative bleeding (mL/12h8) 
ii) blood transfusion (number of pts.9) 
iii) haemoglobin concentration (g/L10) 
565±150 
1/10 (10%)  
110±12 
830±268 
3/10 (30%) 
98±8 
<0.01 
0.29 
0.018 
Karlsson M et al., 
2009 [47] 
 
i) signs of thromboembolism: 
perioperative MI6 
peripheral pulmonary embolus 
(subclincally) 
ii) graft occlusion: 
LIMA LAD7 graft patency 
vein graft patency 
 
0 
 
1 
 
100% 
94% (16/17) 
 
1 
 
0 
 
100% 
100% (20) 
 
 
 
 
 
 
0.46 
iv) global haemostasis no significant differences in ROTEM® vari-
ables between I11 and C12 at any point in time  
i) maximum velocity of clot formation according to authors significantly better in I 
versus C but not further specified 
 
ii) platelet function 
iii) thrombin generation 
no data provided 
iv) perioperative blood loss according to authors comparable between I 
and C but not further specified 
Fenger-Eriksen C et 
al., 2009 [44] 
MCF13 according to authors significantly better in I 
versus C but not further specified 
v) blood product transfusion 
perioperative RBC (u) 
postoperative RBC during 48h (u) 
pts. transfused with RBC during 48 h  
 
2.0 (0-6) 
1.5 (0-2) 
20% (2/10) 
 
2.5 (0-5) 
0 (0-2) 
80% (8/10) 
 
0.91 
<0.05 
<0.05 
_____________________________________________________ 
1 u = units 
2 RBC =red blood cells 
3 FFP = fresh frozen plasma 
4 PC =platelet concentrate 
5 mL = millilitre 
6 MI = myocardial infarction 
7 LIMA LAD = left internal mammary artery/ left anterior descending coronary artery 
8 h = hours 
9 pts = patients 
10 g/L = gram per litre 
11 I = intervention group 
12 C= control group 
13 MCF = maximum clot firmness 
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Rahe-Meyer N et al. (2009) [46] assessed the efficacy of fibrinogen concen-
trate infusion in patients undergoing elective thoracoabdominal aortic aneu-
rysma (TAAA) surgery in a cohort study consisting of a prospective study 
group (n10=6) and a retrospective control group (n=12). The historical con-
trol encompassed all patients who underwent elective TAAA surgery at 
Hannover Medical School in 2006. The characteristics of the study groups at 
the beginning of the study were similar with regard to age, weight, BMI, sex, 
and comorbidities. However, the intraoperative cardiopulmonary bypass 
time differed substantially between the intervention (111 ± 35 minutes) and 
the control group (139 ± 79 minutes, p-value not stated). The study group 
received fibrinogen concentrate (Haemocomplettan® P) prior to a standard 
transfusion algorithm, if intraoperative blood loss was between 60 and 250 g, 
a threshold empirically set by the authors. Dosing of fibrinogen concentrate 
was calculated by applying a formula in order to obtain a MCF of 22 mm in 
the ROTEM® FIBTEM test, which – according to the authors – translates 
into a plasma fibrinogen level of 3.6 g/L. The mean amount of fibrinogen 
administered was 7.8 ± 2.7 g. The historical control had received blood 
products, including platelet concentrates and FFP, according to a standard 
transfusion algorithm. The primary outcome measures were transfusion of 
allogeneic blood products during surgery and 24 hours (h) postoperatively. 
Secondary outcomes encompassed the number of patients without any trans-
fusion during 24 h postoperatively and 24 h postoperative drainage volume. 
Overall, the intervention group needed significantly less blood products, in-
cluding RBC concentrates, platelets, and FFP, than the historical control. In 
addition, all patients (100%) in the control group were in need of transfusion 
of blood products during 24 h postoperatively as compared to only 33% in 
the intervention group. This difference was statistically significant as was the 
difference in 24 h postoperative drainage volume in favour of the interven-
tion group.  
Rahe-Meyer N et al. (2009) [45] compared the haemostatic effects of conven-
tional transfusion management and fibrinogen concentrate administration in 
patients undergoing aortic valve operation and ascending aorta replacement 
(AV-AA) in a cohort study. Both the study group (n=10) and the control 
group (n=5) were assessed prospectively, whereas data from a historical con-
trol (n=42), including all patients who underwent elective AV-AA in 2006, 
were used to develop a standard transfusion algorithm. There were no sig-
nificant differences between the three study groups with respect to age, 
weight, BMI, sex, and comorbidities. However, hours spent in the intensive 
care unit differed significantly (p<0.05) between the study (20 h; 5 h SD11) 
and the control group (31 h; 21 h SD). In addition, patients in the interven-
tion group spent a mean of 10 days (2 days SD) in hospital, whereas indi-
viduals in the control group spent a mean of 12 days (12 days SD) in hospital. 
The intervention group received fibrinogen concentrate (Haemocomplettan® 
P) prior to the standard transfusion algorithm, if intraoperative blood loss 
was between 60 and 250 g, a threshold empirically set by the authors.  Fi-
brinogen concentrate dosing was calculated according to a formula with the 
aim of obtaining a MCF in the ROTEM® FIBTEM test of about 22 mm. The 
mean amount of fibrinogen substituted was 5.7 g (0.7 g SD). Patients in the 
prospective control group were transfused according to the standard transfu-
sion algorithm. Primary outcome was transfusion requirements of allogeneic 
                                                               
10
 n = number 
11
 SD = Standard Deviation 
18 pts, 6 in intervention 
group, TAAA surgery; 
cohort study 
 
 
 
 
 
mean fibrinogen 
substitution 7.8 ± 2.7 g 
 
 
 
 
100% in control vs. 33% 
in intervention group 
were in need of 
transfusion 
15 pts, 10 in 
intervention group, AV-
AA surgery; cohort 
study 
 
 
 
 
mean fibrinogen 
substitution 5.7 g (0.7 g 
SD) 
 
Haemocomplettan® P alone or in combination with Fibrogammin® P in acquired hypofibrinogenemia 
 
24 LBI-HTA | 2009 
blood products during 24 h postoperatively. Secondary outcome was the 24 h 
postoperative drainage volume. Both the transfusion of allogeneic blood 
products, including RBC concentrates, platelets and FFP, as well as the 24 h 
postoperative drainage volume were significantly decreased in the interven-
tion compared to the control group.  
Karlsson M et al. (2009) [47] explored the feasibility of prophylactic infusion 
of fibrinogen concentrate to patients who underwent coronary artery bypass 
graft (CABG) surgery at Sahlgrenska University Hospital, Sweden between 
September and December 2006 in a prospective, randomised controlled 
phase I-II study comprising ten patients each in the intervention and the 
control group. Baseline characteristics between the two groups were compa-
rable with regard to age, BMI, sex, smoking status, preoperative aspi-
rin/clopidogrel treatment, and euroSCORE risk stratification index. Partici-
pants allocated to the intervention group received 2 g fibrinogen concentrate 
intravenously prior to surgery, whereas individuals in the control group nei-
ther received fibrinogen nor placebo. The primary outcome was clinical ad-
verse events, including signs of central or peripheral thrombembolism, respi-
ratory or circulatory failure, or allergic reactions. Secondary endpoints en-
compassed postoperative bleeding, transfusion of blood products, haemoglo-
bin concentration 24 h postoperatively, and effects of fibrinogen infusion on 
global haemostasis 2 h and 24 h postoperatively. Regarding primary out-
comes, one patient in the control group developed a myocardial infarction 
perioperatively. One participant allocated to the intervention group experi-
enced a subclinical – as detected by computed tomography – peripheral pul-
monary embolus. There were no statistically significant differences in the 
LIMA LAD12 graft patency and the vein graft patency between the two 
groups. In terms of secondary outcomes, the intervention group showed de-
creased postoperative bleeding and increased haemoglobin concentration 
compared to the control group. No significant differences, however, could be 
observed in the requirement of blood transfusions in the first 12 h postopera-
tively as well as the global haemostasis 2 h and 24 h postoperatively between 
the two groups.  
                                                               
12 LIMA LAD = left internal mammary artery/ left anterior descending coronary ar-
tery 
decreased transfusion 
requirements in 
intervention group 
20 pts, 10 in 
intervention group, 
CABG surgery; 
randomised controlled 
phase I-II study 
 
 
 
2 g fibrinogen prior to 
surgery 
 
 
 
 
no differecens in 
postoperative 
transfusion 
requirements 
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Fenger-Eriksen C et al. (2009) [44] assessed the hemostatic effect of fibrinogen 
concentrate substitution in coagulopathy after haemodilution with hy-
droxyethyl starch (HES) 130/0.4 in patients undergoing elective radical cys-
tectomy in a sinlge-centre, prospective, double-blind, randomised placebo-
controlled trial. The intervention (n=11) and control group (n=10) were 
comparable at baseline with regard to age and body mass index. In all pa-
tients perioperative blood loss was substituted with HES 130/0.4 until hema-
tocrit levels were reduced by 30% compared to baseline values. Then, partici-
pants were randomly allocated to either the intervention or the control arm. 
Patients in the intervention group received 45 milligram per kilogram 
(mg/kg) fibrinogen concentrate, whereas patients in the control group re-
ceived 2.25 mg/kg isotonic saline 0.9%. The primary outcome measure was 
MCF as determined by ROTEM® thrombelastometry. Secondary outcomes 
encompassed further ROTEM® variables, platelet function, thrombin genera-
tion, bleeding, and peri- and postoperative blood products transfused. The 
authors state that MCF was significantly better in the intervention than in 
the control group. In terms of secondary endpoints, the maximum velocity of 
clot formation was significantly better in the fibrinogen group than in the 
placebo group, whereas blood loss was comparable between the two arms. No 
data is provided on platelet function and thrombin generation. Regarding 
transfusion requirements for RBC, FFP, and platelets, thresholds were pre-
defined according to internal and national guidelines, respecitvely. 80% 
(8/10) of patients in the placebo group were in need of RBC within 48 h post-
operatively compared to 20% (2/10) in the intervention group (p<0.05). Fur-
thermore, significantly less units of RBC were administered postoperatively 
to the intervention group compared to the control group, whereas periopera-
tively this figure was not different between groups. In terms of FFP substitu-
tion, both intraoperatively and postoperatively no differences were observed 
between the two arms. No patients in either group needed platelets.  
Safety and Mortality 
Overall, we identified nine studies [45-54], assessing the safety and mortality 
of administration of fibrinogen concentrate in patients with acquired hypofi-
brinogenemia. The results of these studies are outlined in table 6.1.1-3 and in 
table 6.1.1-4. 
Table 6.1.1-3: Safety of Haemocomplettan® P in acquired hypofibrinogenemia 
Adverse events Mortality 
author, year, reference no.
events interven-tion control cause intervention control
Rahe-Meyer N et al., 2009 
[46] 
re-exploration for bleeding 
major neurological events 
renal failure 
postoperative atrial fibrillation
0 
0 
0 
0 
4 (33%) 
2 (17%) 
2 (17%) 
1 (8%) 
30-day 
mortality 
 
0 2 (17%)
Rahe-Meyer N et al., 2009 
[45] 
re-exploration for bleeding 
major neurological events 
postoperative atrial fibrillation
0 
0 
1 (10%) 
1 (20%) 
0 
1 (20%) 
30-day 
mortality 
 
0 0 
Karlsson M et al., 2009 
[47] 
myocardial infarction 
(subclinical) peripheral pulmo-
nary embolus  
0 
1 
1 
0 
   
 
21 pts, 11 in intervention 
group, radical 
cystectomy; double-
blind RCT 
 
 
 
45 mg/kg fibrinogen 
concentrate vs. 2.25 
mg/kg isotonic saline 
0.9% 
 
 
 
 
 
decreased postoperative 
transfusion 
requirements in 
intervention group  
 
 
9 studies 
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In the cohort study by Rahe-Meyer N et al. (2009) [46] of patients undergoing 
TAAA surgery neither adverse events nor deaths occurred in the prospective 
intervention group (n=6). In comparison, in the historical control in 33% 
(4/12) of patients re-exploration for bleeding had to be done, 17% (2/12) ex-
perienced a major neurological event, 17% (2/12) had a renal failure, and an-
other 8% (1/12) had postoperative atrial fibrillation. In addition, 30 days 
postoperatively 17% (2/12) of patients had died.  
In the second cohort study conducted by Rahe-Meyer N et al. (2009) of pa-
tients undergoing AV-AA the only adverse event in the intervention group 
was postoperative atrial fibrillation in 10% (1/10) of patients as compared to 
20% (1/5) of patients in the control arm. Moreover, 20% (1/5) of patients in 
the control were in need of re-exploration for bleeding. No major neurologi-
cal events occurred in either group. 30 days after surgery all individuals, re-
gardless of the assigned group, were alive 
In the study by Karlsson M et al. (2009) [47] of CABG patients one partici-
pant in the intervention group (n=10) developed a subclinical peripheral 
pulmonary embolus and one patient in the control group (n=10) experienced 
a perioperative myocardial infarction. 
 
adverse events and 
deaths only in the 
control group 
postoperative atrial 
fibrillation in  1/ 10 pts 
in intervention group  
subclinical peripheral 
pulmonary embolus in 
1/ 10 pts in intervention 
group 
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Table 6.1.1-4: All safety studies of Haemocomplettan® P in acquired hypofibrinogenemia  
author, year, reference 
no. 
study design/ 
dose of fibrinogen ad-
ministered 
funding patient  population 
number of 
patients 
adverse 
events  mortality comments 
Rahe-Meyer N et al., 
2009 [46] 
prospective/ mean 
7.8±2.7g1 
CSL Behring, Marburg, Germany 
 TAAA
2 surgery 6 0 0 
 adverse events and deaths in the control 
possibly related to more severely ill pts.3 
included in the control group 
Rahe-Meyer N et al., 
2009 [45] 
prospective/ mean 7.5g 
(0.7g SD4) 
CSL Behring, Marburg, Germany 
 AV-AA
5 surgery 10 1 0 
adverse events in the control possibly re-
lated to more severely ill pts. included in 
the control group 
Karlsson M et al., 2009 
[47] prospective/ 2g 
CSL Behring, Marburg, Germany; 
Sahlgrenska University Hospital, 
Sweden; 
Swedish Heart & Lung Foundation
CABG6 patients 10 1 not speci-fied randomised controlled trial 
Dickneite G et al., 2009 
(CSL Behring) [48] 
retrospective/ not speci-
fied CSL Behring, Marburg, Germany 
congenital and acquired hypofibrinogene-
mia 
not speci-
fied 9 
not speci-
fied parmacosurveillance over 22 years 
Weinkove R et Ranga-
rajan S (2008) [49] 
retrospective/median 
4g  no information provided 
placental abruption, massive blood loss and 
transfusion, liver failure, postcardiac sur-
gery, others 
30 10 (33%) 12 (40%) 
one death prior to fibrinogen concentrate 
administration; not specified whether ad-
verse events and deaths were related to fi-
brinogen substitution 
Farriols Dane´s A et al. 
(2008) [50] 
retrospective/median 
4g CSL Behring, Marburg, Germany 
sepsis, upper gastrointestinal tract hemor-
rhage, gynaecological diseases, sur-
gery/trauma, haematological malignancy, 
liver transplantation, liver insufficiency, 
other 
69 o 30 (44.2%) 
according to authors higher plasma fi-
brinogen levels were associated with in-
creased survival; causes of death not speci-
fied 
Fenger-Eriksen C et al. 
(2008) [51] 
retrospective/2g in 
adults, 0.35g in children no information provided 
obstetric complications, paediatric, cardio-
thoracic bleeding, intra-abdominal bleed-
ing, trauma, other 
43 2 (5%) 9 (21%) 
according to authors no serious adverse 
events related to fibrinogen substitution, 
causes of death: bleeding (8), not specified 
(1) 
Haas T et al. (2008) 
[52] 
retrospective/ 76 (67 ; 
100) mg/kg6 no information provided craniosynostosis surgery  9 0 0 
children: median age 12 months (25th; 75th 
percentile: 8; 22) 
Schopen G  et al. (1994) 
[54]/ Bonik K et al. 
(1996) [53] 
retrospective/mean 
5.6g/ mean 5.2g 
Behringwerke AG, Liederbach, 
Germany/ Centcom Pharma GmbH, 
Liederbach, Germany 
hemorrhages, liver insufficiency, dissemi-
nated intravascular coagulation, hyperfi-
brinolysis, leukaemias 
51/ 94 0/ 2 (2%) 16 (31%)/ 20 (21%) 
according to authors none of the deaths is 
related to fibrinogen concentration ad-
ministration but causes of death are not 
stated  
_______________________________________________ 
1 g = gram 
2 TAAA = thoracoabdominal aortic aneurysma 
3 pts = patients 
4 SD = standard deviation 
5 CABG = coronary artery bypass graft 
6 mg/kg = milligram per kilogram 
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Recently pharmacosurveillance data published by Dickneite G et al. (CSL 
Behring) (2009) [48] has become available. According to this report , be-
tween 1 January 1986 and 31 August 2008, overall 1,034,389 g of Haemocom-
plettan® P were handed out across 21 European, Asian, and African coun-
tries, equalling around € 364.5 million, if calculated with Austrian prices. 
Over these 22 years, nine cases of central or peripheral thrombosis suspected 
to be related to fibrinogen concentrate administration were reported, two of 
which occurred in patients with acquired hypofibrinogenemia. One of these 
patients was an adult who recovered, the other one was a neonate who died 
subsequently. The authors estimated the incidence of thrombosis as having 
been 3.48 (95% CI13: 1.59; 6.61) per 100,000 treatment episodes.  
Weinkove R et Rangarajan S (2008) [49] retrospectively reviewed data of a 
heterogeneous population of 30 adults with acquired hypofibrinogenemia 
who had received Haemocomplettan® P in a single institution. Overall, of the 
30 adults, 12 (40%) patients died in hospital and 10 individuals (33%) experi-
enced adverse events. Causes of death included persistent bleeding (6), sepsis 
(2), myocardial infarction (2, of which one occurred prior to fibrinogen con-
centrate administration), liver failure (1), and disseminated carcinoma (1). 
Adverse events encompassed ischaemic cerebrovascular events (3) and myo-
cardial infarction (1), all of which occurred between 4 and 12 days following 
fibrinogen administration. However, according to the authors those four is-
chaemic events were not related to fibrinogen administration. Furthermore, 
in 4 (50%) women with placental abruption the foetus died in utero, and an-
other 2 (25%) had to undergo an emergency hysterectomy.  
Farriols Danés A et al. (2008) [50] retrospectively assessed the therapeutic ef-
fect of fibrinogen concentrate administration in 69 patients with acute as well 
as chronic acquired hypofibrinogenemia due to various underlying clinical 
conditions in a third-level hospital. 58% of individuals were female. Causes of 
acute fibrinogen deficiency comprised sepsis, upper gastrointestinal tract 
haemorrhage, gynaecological diseases, surgery/ trauma, and others. Chronic 
fibrinogen deficiency encompassed various underlying diseases, such as hae-
matological malignancies, liver transplantation, and hepatic insufficiency. 
32.3% and 44.2% of individuals had died in hospital after 24h and 72h, re-
spectively. According to the authors, no severe adverse events occurred.  
Fenger-Eriksen C et al. (2008) [51] retrospectively explored the effects of fi-
brinogen concentrate administration in a heterogeneous population of 43 pa-
tients with acquired hypofibrinogenemia in serious hemorrhage in a single 
centre. 65% of individuals were female. Of the 43 patients, 8 (18%) had died 
intraoperatively and another one had died the day after surgery, adding up to 
9 (21%) inpatient deaths. A further two (5%) patients experienced adverse 
events, including jitter and snoring respiration as well as attacks of shivering. 
Haas T et al. (2008) [52] audited fibrinogen concentrate administration in 9 
children who had undergone surgery for craniosynostosis repair in a single 
institution. According to the authors, no bleeding complications or throm-
bembolic events occurred in any of the children during their hospital stay.  
Schopen G et al. (1994) [54] carried out an interim-analysis of a post-
marketing drug monitoring study on Haemocomplettan® P in 67 patients 
with acquired hypofibrinogenemia, of whom 51 males and females were 
evaluated. The authors state that no adverse events, particularly no throm-
                                                               
13 CI = confidence interval 
1,034,389 gram of 
Haemocomplettan® P 
distributed over 22 
years 
 
9 cases of thrombosis in 
22 years – 3.48 per 
100,000 treatment 
episodes 
 
30 pts, 33% adverse 
events, 12% deaths – 6/ 
30 died from persistent 
bleeding 
69 pts, no adverse 
events, 44% died within 
72 hours 
43 pts, 5% adverse 
events, 21 % inpatient 
deaths 
9 children, no adverse 
events, no deaths 
67 pts, no adverse 
events, 31% of pts died 
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bembolic complications, occurred. Nevertheless, 16 (31%) individuals died. 
According to the authors, these deaths were not caused by fibrinogen concen-
trate administration. However, causes of death are not specified.  
In the final analysis of this postmarketing drug monitoring study 96 patients 
with acquired hypofibrinogenemia across 36 hospitals in Germany were 
evaluated by Bonik K et al. (1996) [53]. However, 94 individuals were finally 
assessed for tolerability of fibrinogen concentrate. 20 (21%) patients died and 
a further two (2%) experienced adverse events, namely elevated body tem-
perature. The authors claim that none of the deaths was related to fibrinogen 
concentrate administration but causes of death remain unclear.  
6.1.2 Fibrogammin® P 
Efficacy 
One prospective, randomised, double-blind, placebo-controlled study [55] 
encompassing 22 patients could be found. Information on the trial is summa-
rised in table 6.1.2-1 and in table 6.1.2-2.  
Korte WC et al. (2009) [55] evaluated whether preoperative administration of 
factor XIII has positive effects on clot firmness and therefore prevents pa-
tients from blood loss. Patients undergoing various elective surgical proce-
dures for gastrointestinal cancer who were at increased risk of intraoperative 
blood loss, defined as elevated preoperative fibrin monomer level of more 
than 3 microgram per litre (μg/L), were included. A pre-planned interim 
analysis was done on 22 patients as an intention-to-treat analysis. Seven out 
of these 22 patients were female (32%). According to the authors, the charac-
teristics of the study groups at the beginning of the study were similar with 
regard to body mass index, age and American Society of Anaesthesiology 
physical status classification scores. The intervention group received Fibro-
gammin (30U/kg) intravenously (IV) 15 minutes into surgery, whereas pla-
cebo (Albumin) was administered to the control group. The primary out-
come measure was the reduction in MCF 195 minutes into surgery as deter-
mined by ROTEM® thrombelastometry. A range of secondary endpoints was 
assessed as well. Regarding the primary endpoint, the difference in the reduc-
tion in MCF 195 minutes into surgery was statistically significant (p=0.004) 
and was 7% in the intervention as compared to 38% in the placebo group. In 
terms of secondary outcomes, significant differences were observed for me-
dian overall blood loss which was 750 mL in the intervention and 1050 mL 
in the control group (p=0.041), and for fibrinogen consumption at 195 min-
utes showing a decrease by 28% in the study group compared to the placebo 
group (p=0.01). All other secondary outcomes, such as transfusion of blood 
products, volume support, and length of surgery besides others, did not show 
significant differences between the two arms.  
 
96 pts, 2% adverse 
events, 21% of pts died 
1 study, 22 pts  
22 pts, surgery for 
gastrointestinal cancer; 
double-blind, placebo-
controlled study 
 
 
 
 
30U/kg Fibrogammin® P 
versus Albumin  
 
 
 
 
no differences in 
transfusion 
requirements 
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Table 6.1.2-1: Efficacy of Fibrogammin® P  
____________________________________ 
1 pts = patients 
2 μg/L = microgram per litre 
3 n = number 
4 I = intervention group 
5 U/kg = units per kilogram  
6 C = control group 
 
7 min = minutes  
8 F1+2 =prothrombin fragments 
 
 
Table 6.1.2-2: Results of efficacy of Fibrogammin® P  
Results author, year, reference 
no. primary outcome interven-tion 
con-
trol p-value secondary outcomes intervention control p-value 
median overall blood loss (mL3) 
 
fibrinogen consumption at 195min. 
750; (-29%) 
 
-28% 
1050  0.041 
 
0.01 
Korte C et al., 2009 
[55] 
reduction in MCF1 after 
195min.2 
 
 
 
7% 38% 0.004 
no statistically significant differences between the intervention and the control group with regard to 
prothrombin conversion, IV4 fluids, transfusion of RBC5, FFP6, or platelets, pH, body temperature and 
length of surgery 
__________________________________ 
1 MCF = maximum clot firmness 
2 min = minutes 
 
3 mL = millilitre 
4 IV = intravenous 
 
5 RBC = red blood cells 
6 FFP = fresh frozen plasma 
author, 
year, refe-
rence no. 
funding/ 
setting aim 
study design/ 
study population intervention primary/ secondary outcomes 
Korte C et 
al., 2009 
[55] 
CSL Behring, Bern, Switzerland; 
CSL Behring, Hattersheim, Germany; 
Dade Behring, Marburg, Germany;  
Pentapharm, Basel, Switzerland; 
Novo Nordisk, Zurich, Switzerland; 
Institute for Clinical Chemistry and 
Haematology and Institute for Anes-
thesiology, Kantonsspital St. Gallen, St. 
Gallen, Switzerland/ Kantonsspital St. 
Gallen, St. Gallen, Switzerland 
proof of concept study in order 
to confirm that pts.1 at high risk 
for intraoperative blood loss 
show reduced loss of clot firm-
ness when factor XIII is adminis-
tered early during surgery 
prospective, randomised, double-blind, 
placebo-controlled; pts. undergoing  
elective gastro-intestinal cancer sur-
gery at increased risk for intraperative 
blood loss as measured by preopera-
tive fibrin monomer levels >3μg/L2 
(n3=22) 
I4: study medication = 
factor XIII (Fibro-
gammin) 30U/kg5; 
trigger: 15min7. after be-
ginning of surgery 
 
C6: placebo = Albumin  
primary: maximum clot firmness  
(MCF) assessed by ROTEM®; 
secondary: median factor XIII activity; 
prothrombin conversion as measured by 
F1+28; 
fibrinogen level; 
reduction in red blood cell support and in-
fusion volume; 
lowest ph and lowest body temperature; 
length of surgery;  
median overall blood loss 
Extraction of data 
 
LBI-HTA | 2009 31 
Safety and Mortality 
As can be seen in table 6.1.2-3, in the study by Korte WC et al. (2009) a total 
of three out of 22 patients experienced adverse events, all of whom were as-
signed to the intervention group. According to the authors, these adverse 
events were unlikely to be related to the administration of factor XIII. Ob-
served side effects included one episode of hypotension following the ad-
ministration of Fibrogammin® P in one patient. Furthermore, one patient 
developed a deep vein thrombosis one week after surgery. Another patient 
developed postoperative ascites and pleural empyema with sepsis and died 
from a myocardial infarction 30 days after surgery. In terms of mortality, 
three patients had died in each of the two groups after a median follow-up of 
340 days. The cause of mortality is only stated for one patient in the inter-
vention group, who died from myocardial infarction 30 days after surgery. 
No information is provided about the causes of death in the other five pa-
tients. 
Table 6.1.2-3: Safety of Fibrogammin® P  
Adverse events Mortality 
author, year, 
reference no. events inter-vention control cause 
interven-
tion control 
Korte C et al., 
2009 [55] 
overall 
hypotension 
deep vein thrombosis 
postoperative ascites  
pleural empyema with sepsis 
myocardial infarction 
3 
1 
1 
1 
1 
1 
0 
0 
0 
0 
0 
0 
overall  
not stated 
myocardial 
infarction 
3 
2 
1 
3 
3 
0 
 
6.1.3 Comparison ROTEM® rotational 
thrombelastometry/standard laboratory 
hemostasis tests 
Three studies were identified evaluating the ability of rotational thrombelas-
tometry in detecting coagulation disorders and guiding blood transfusions, 
respectively, as well as exploring correlations between ROTEM® and stan-
dard laboratory hemostasis tests [32, 35, 36]. Results of the studies are shown 
in table 6.1.3-1. Two of these – both published in 2006 - are prospective, ob-
servational, single-arm studies. The remainder – published in 2009 - is a 
comparative observational study with a prospective intervention and a his-
torical control group. In total, 147 patients were assessed, comprising a het-
erogeneous patient population, including patients undergoing orthotopic 
liver transplantation (OLT), trauma patients and women experiencing post-
partum haemorrhage (PPH). 
 
adverse events in 3/ 22 
pts 
 
 
 
 
 
 
6 pts died 
3 studies, 147 pts, liver 
transplant, trauma, 
postpartum 
haemorrhage  
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Table 6.1.3-1: Use of ROTEM® rotational thrombelastometry to detect fibrinogen deficiency in acquired hypofibrinogenemia 
author, year, 
reference no. funding aim 
study design/ study 
population 
cut-off values 
Clauss fibrino-
gen assay 
cut-off values 
ROTEM® FIBTEM test accuracy 
correlation/ 
agreement 
Coakley M et 
al., 2006 [32] 
no information pro-
vided 
compare extent to which admini-
stration of blood products would 
be indicated using ROTEM®/ 
conventional coagulation tests in 
pts.1 undergoing OLT2 
prospective, observa-
tional, single-arm, n3=20 
OLT pts. 
fibrinogen <1 
g/L4; met in 
39% of samples 
FIBTEM 
MA5=MCF6 
<8mm; met in 
55% of samples 
not specified Pearson’s correlation: signifi-
cant correlation r=0.75; 
p7≤0.01 
 
Kappa-analysis: 
moderate agreement k=0.42; 
p≤0.05 
Rugeri L et 
al., 2006 
[36] 
BIODIS, Signes, 
France 
assess ability of ROTEM® to de-
tect various coagulation disor-
ders in trauma pts. and its use-
fulness in guiding transfusion of 
blood products 
prospective, observa-
tional, single-arm, n=90 
trauma pts.  
fibrinogen <1 
g/L 
CA108-
FIBTEM=5mm9 
sensitivity  
 
specificity  
 
PPV10  
 
NPV11 
91% (72; 93) 
 
85% (84; 86) 
 
55% (45; 60) 
 
99% (97; 100) 
Spearman’s rank test:  
significant correlation  
r=0.85; p≤0.001 
Huissoud C 
et al., 2009 
[35] 
none evaluate ability of ROTEM®  to 
early detect decrease in fibrino-
gen levels in PPH12 
prospective, observa-
tional, n=91 women: 
prospective study group 
with PPH, n=37; 
retrospective control 
group without PPH, 
n=54 
fibrinogen <1 
g/L 
 
 
CA5-13/ CA1514-
FIBTEM= 
4mm/ 5mm 
 
 
sensitivity  
 
specificity 
 
 
PPV 
 
 
NPV 
100/ 100%  
 
86% (76; 96)/ 
88% (79; 97) 
 
13% (3; 22)/ 
14% (5; 24) 
 
100/ 100% 
Spearman’s rank test:  
fibrinogen/CA5   
r= I15: 0.86; p<0.0001 vs.16 C17: 
0.83; p<0.0001 
 
fibrinogen/CA15  
r= I: 0.84; p<0.0001 vs. C: 
0.83; p<0.0001 
_____________________________________ 
1 pts = patients 
2 OLT = orthotopic liver transplantation 
3 n = number 
4 g = gram per litre 
5 MA = maximum amplitude 
6 MCF = maxiumum clot firmness 
7 p = p-value 
8 CA10 = clot amplitude at 10 minutes 
9 mm = millimetre 
10 PPV= positive predictive value 
11 NPV = negative predictive value 
12 PPH = postpartum hemorrhage 
13 CA5 = clot amplitude at 5 minutes 
14 CA15 = clot amplitude at 15 minutes 
15 I = intervention group 
16 vs = versus 
17 C = control group 
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Coakley M et al. (2006) [32] employed both ROTEM® thrombelastostometry 
and conventional coagulation tests in 20 patients undergoing OLT in a pro-
spective, observational, single-arm study. Overall, there was a significant cor-
relation between ROTEM® FIBTEM maximum amplitude (MA) = MCF 
and Clauss fibrinogen (r=0.75; p≤0.01) but only moderate agreement be-
tween ROTEM® FIBTEM MA results and Clauss fibrinogen results as to 
when substitute fibrinogen (k=0.42; p≤0.05). ROTEM® FIBTEM met crite-
ria for fibrinogen transfusion – defined as FIBTEM MA/MCF <8mm - in 
55% of blood samples, whereas Clauss fibrinogen assay met criteria for re-
placement of fibrinogen – defined as <1 g/L – in only 39% of blood samples 
taken.  
Rugeri L et al. (2006) [36] compared ROTEM® thrombelastostometry and 
conventional coagulation tests in a prospective, observational, single-arm 
study comprising 90 trauma patients, 23% of whom were female. The authors 
defined normal ROTEM® values based on blood samples taken from 70 
healthy individuals, 30% of whom were female. Correlations were assessed 
for fibrinogen level and clot amplitude at 10 minutes (CA10)-FIBTEM 
(r=0.85; p<0.001), prothrombin time (PT) and clot amplitude at 15 minutes 
(CA15) -EXTEM (r=0.66; p<0.001), activated partial thromboplastin time 
(aPTT) and clot formation time (CFT)-INTEM (r=0.91; p<0.001) as well as 
for platelet count and CA15-INTEM (r=0.57; p<0.001). The ROTEM
® cut-
off parameter for fibrinogen was CA10-FIBTEM of 5 mm corresponding to a 
fibrinogen level as determined by Clauss assay of <1 g/L. ROTEM® FIB-
TEM showed a sensitivity of 91% and a specificity of 85%. Although the test 
had a high NPV of 99%, indicating that in 99% of negative test results a fi-
brinogen level <1g/L can be ruled out, the PPV was only 55%. Therefore, in 
only 55% of positive test results the fibrinogen level truly was less than 1 g/L. 
Huissoud C et al. (2009) [35] conducted an observational study with a prospec-
tive intervention group consisting of 37 women experiencing PPH and a his-
torical control group of 54 women without PPH. The authors explored corre-
lations between ROTEM® FIBTEM test results and fibrinogen level as de-
termined by Clauss assay. A negative correlation could be found between fi-
brinogen level and FIBTEM clotting time (CT) in both the intervention and 
the control group but it was only significant in the control group. Further-
more, positive and statistically significant correlations were found between 
fibrinogen level and FIBTEM CA5/CA15, and MCF in both arms. Cut-off val-
ues for CA5-FIBTEM were 6/5/4 mm and for CA15-FIBTEM 8/6/5 mm ac-
cording to Clauss fibrinogen levels of <2/1.5/1 g/L. The sensitivity of RO-
TEM® FIBTEM was 100% in all cut-off values chosen for FIBTEM in PPH, 
whereas the specificity ranged from 84% to 88%. The NPV was 100% in all 
cut-off values but the PPV decreased steadily from 50/46% in CA5-/CA15-
FIBTEM 6/8 mm – according to fibrinogen levels of <2 g/l - to only 13/14% 
in CA5-/CA15-FIBTEM 4/5 mm – corresponding to fibrinogen levels of <1 
g/L.  
 
 
 
20 liver transplant pts 
 
fibrinogen cut-off <1 
g/L: Clauss 39% vs. 
ROTEM® 55% of 
samples suggest 
substitution  
 
90 trauma pts 
 
 
 
ROTEM® FIBTEM: PPV 
55%, i.e. in only 55% of 
positive tests the 
fibrinogen level truly 
was <1 g/L 
 
 
37 postpartum 
hemorrhage pts  
 
 
 
ROTEM® FIBTEM: PPV 
50%  (according to 
fibrinogen level <2 g/L) 
decreased to 13% 
(according to fibrinogen 
level <1 g/L) 
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6.1.4 Comparison transfusion requirements and 
costs before/ after implementation of 
ROTEM® rotational thrombelastometry 
Two studies [40, 41] – comprising 2412 patients overall - could be identified 
comparing transfusion requirements, including number of patients trans-
fused with blood products as well as units of blood products transfused, pa-
tient-relevant outcomes, and costs, during six months before and after im-
plementation of ROTEM® rotational thrombelastometry in two cardiac sur-
gery units. The results of these studies are summarised in table 6.1.4-1 and in 
table 6.1.4-2. 
Anderson L et al. (2006) [40] evaluated the reduction in the consumption of 
RBC, FFP and platelets associated with the implementation of ROTEM® 
thrombelastometry for postoperative transfusion management in 990 sequen-
tial patients in a cardiac intensive care unit in 2001/ 2002. The authors 
showed statistically significant decreases both in the number of patients 
transfused with RBC, FFP, and platelets as well as in the units of blood 
products transfused after ROTEM® implementation compared to the period 
before its use. However, no significant differences were observed in patient-
relevant outcomes, including discharge haemoglobin level, length of stay in 
intensive care unit and hospital, and surgical re-exploration.  
Spalding GJ et al. (2007) [41] assessed the reduction in treatment costs of 
1422 cardiosurgical patients associated with ROTEM® implementation in a 
single institution within one year. The authors concluded that there was a 
significant decrease in the monthly consumption of platelets and FXIII but 
not in the use of RBC and FFP, along with an increase in fibrinogen con-
sumption. Furthermore, overall monthly costs for blood products and factor 
concentrates decreased from € 125,828 to € 55,925. Declines could be seen in 
the costs for RBC, FFP, platelets, and FXIII, whereas at the same time costs 
for fibrinogen rose almost four-fold from € 4,025 before to € 15,812 after 
ROTEM® implementation. 
 
2 studies, 2412 pts  
990 pts, cardiac 
intensive care unit 
 
no difference in patient-
relevant outcomes 
1422 cardiosurgical pts 
 
 
reduced overall costs 
 
 
Extraction of data 
 
LBI-HTA | 2009 35 
Table 6.1.4-1: Comparison of transfusion requirements and costs in acquired hypofibrinogenemia in cardiosurgical patients before and after ROTEM® implementation  
author, year, 
reference no. funding aim 
study design/  
study population inclusion/exclusion criteria 
characteristics of the study groups at the be-
ginning of the study primary outcomes  
Anderson L 
et al., 2006 
[40] 
Scottish National 
Blood Transfusion 
Serivce 
evaluate the reduction 
in the consumption of 
RBC, FFP and platelets 
associated with the im-
plementation of RO-
TEM® thrombelastome-
try 
before/after study; retrospective 
analysis; n=990 sequential pts. 
 
period 1 = before implementation 
of ROTEM® = July 2001 to De-
cember 2001; n=488 pts. 
 
period 2 = after implementation 
of ROTEM® = February 2002 to 
July 2002; n=502 pts. 
postoperative transfusion man-
agement in a cardiac intensive 
care unit: 
 
inclusion period 1: excessive 
bleeding postoperatively as de-
fined by fulfilling certain crite-
ria, if requested by the surgeon 
or anaesthesist vs. period 2: not 
specified 
 
no significant differences between the two 
groups with regard to age, gender, preoperative 
haemoglobin concentration, platelet count, fi-
brinogen concentration, and INR, valve surgery, 
cross clamp time; 
 
significant differences between the two groups 
with regard to EuroSCORE risk index, preopera-
tive PTT, coronary artery bypass grafting, com-
bined valve/bypass surgery, time in theatre, by-
pass time 
discharge Hb (g/dL) 
 
length of stay in inten-
sive care unit (hours) 
 
length of stay in hospi-
tal (days) 
 
surgical re-exploration 
Spalding GJ 
et al., 2007 
[41] 
no information 
provided 
evaluate the reduction 
in treatment costs of 
cardiosurgical patients 
associated with the im-
plementation of RO-
TEM® 
before/after study 
 
period 1 = before implementation 
of ROTEM®; n=729 pts. 
 
period 2 = after implementation 
of ROTEM®; n=693 pts. 
all pts. undergoing cardiac sur-
gery in a single institution 
within one year 
 
 
no significant differences between the two 
groups with regard to age, gender, cardiac sur-
gery procedure, early mortality, early rester-
notomy 
 
significant difference between the two groups 
with regard to EuroSCORE risk index 
not specified 
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Table 6.1.4-2: Results of studies assessing transfusion requirements and costs before and after ROTEM®implementation  
Results 
author, year, reference no. transfusion requirements, patient-relevant outcomes, costs before ROTEM®-implementation after ROTEM®-implementation p-value 
number of pts.1 transfused with  
 
RBC2 
FFP3 
platelets 
294/488 (60%) 
81/488 (17%) 
77/488 (16%) 
270/502 (53%) 
60/502 (12%) 
56/502 (11%) 
0.04 
0.037 
0.033 
units transfused (number) 
 
RBC 
FFP  
platelets  
1094 
343 
96 
931 
271 
75 
0.003 
0.036 
0.032 
Anderson L et al., 2006 [40] 
patient-relevant outcomes discharge Hb4 (g/dL5) 
length of stay in intensive care unit (hours)  
length of stay in hospital (days) 
surgical re-exploration 
10±1.2 
23 
7 
19/488 (4%) 
9.9±1.2 
24 
7 
16/502 (3%) 
n. s.6 
n. s. 
n. s. 
n. s. 
monthly consumption RBC (unit) 
PltC7 (unit)  
FFP (unit)  
PCC8 (500 IU9)  
Fibrinogen (1g10)  
rFVIIa11 (120 IU)  
FXIII12 (1250 IU)  
Aprotinin (2.5 Mio IU)  
Desmopressin (40μg13)  
439 
59 
118 
130 
14 
11 
17 
109 
22 
368 
28 
116 
27 
55 
1 
8 
43 
39 
n. s. 
0.000 
n. s. 
0.000 
n. s. 
0.000 
0.001 
0.000 
0.000 
Spalding GJ et al., 2007 [41] 
monthly costs in Euro 
 
cumulative  
RBC  (1 unit a´ €14 70) 
PltC  (1 unit a´ € 500) 
FFP (1 unit a´ € 51) 
PCC  (500 IU a´ € 120) 
Fibrinogen (1g a´ € 287.5) 
rFVIIa (120 IU a´ €1,512) 
FXIII (1250IU a´ € 405) 
Aprotinin (2.5 Mio IU a´ € 123.75) 
Desmopressin (40μg a´ 134.12) 
€ 125,828 
€ 30,730 
€ 29,500 
€ 6,018 
€ 15,600 
€ 4,025 
€ 16,632 
€ 6,885 
€ 13,488 
€ 2,950 
€ 55,925 
€ 25,620 
€ 14,000 
€ 5,916 
€ 3,240 
€ 15,812 
€ 604 
€ 3,240 
€ 5,321 
€ 5,230 
 
_____________________________________ 
1 pts = patients 
2 RBC = red blood cells 
3 FFP = fresh frozen plasma 
4 Hb = haemoglobin 
5 g/dL = gram per decilitre 
6 ns = not significant 
7 PltC = platelet concentrate 
8 PCC = prothrombin complex concentrate 
9 IU = international units 
10 g = gram 
11 rFVIIa = recombinant clotting factor VIIa (activated)  
12 FXIII = clotting factor XIII 
13 μg = microgram  
14 € = Euro 
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7 Quality of studies 
7.1 Haemocomplettan® P 
We assessed the methodological quality of the two cohort studies by Rahe-
Meyer N et al.  [45, 46] according to the criteria for the evaluation of cohort 
studies outlined in the Internal Manual of the LBI-HTA [43]. In addition, 
we evaluated the methodological quality of the two randomised controlled 
trials by Karlsson M et al. [47] and Fenger-Eriksen et al. [44] according to the 
CONSORT statement for improving the quality of reports of parallel-group 
randomised trials [56]. Overall, the quality of the studies identified is poor. 
On the one hand, results could have been flawed by introducing systematic 
errors. On the other hand, results could have been obtained simply by chance 
as well due to small sample sizes, ranging from 6 to 10 participants in the in-
tervention groups and 5 to 10 individuals in the control groups. 
The major flaw in the study by Rahe-Meyer N et al. (2009) [46] appears to be 
the introduction of selection bias. Although the historical control group 
seems to be a consecutive cohort of patients recruited in a single institution 
during 2006, it remains unclear whether the intervention group was selected 
consecutively as well. Exclusion criteria are clearly stated by the authors and 
the same criteria were applied to both groups. Nevertheless, the historical 
control may have been different from the intervention group because they 
were recruited at different points in time and therefore could have been in-
fluenced by different confounding factors, ultimately leading to selection 
bias. The differences in cardio-pulmonary bypass time, complication rates 
and in-hospital mortality between the two groups suggest that they may have 
been different at baseline, particularly with regard to the severity of TAAA 
with the control group being more severely ill than the intervention group. 
However, baseline data regarding the severity of TAAA to overcome that 
suspicion is lacking. The introduction of measurement bias cannot be ruled 
out as the level of bleeding was assessed differently in the two groups. The 
primary outcome parameter of the trial was the amount of blood products 
substituted postoperatively and it could be shown that less blood products 
were transfused in the intervention group compared to the control group. 
However, given the lack of pre-defined transfusion triggers, this endpoint 
might not have been objective. The authors neither specify the length of fol-
low-up nor the number of patients lost to follow-up in each group which 
could, particularly if different between the two groups, introduce systematic 
errors. Small sample sizes in both groups may have led to results that could 
have been obtained simply by chance as well. Finally, the causes of death in 
two patients in the control group are not stated.  
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different confounding 
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small sample size: 
results obtained by 
chance? 
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In the second cohort study identified by Rahe-Meyer N et al. (2009) [45] se-
lection bias could have arisen as well. It seems that the historical control of 
42 participants was recruited consecutively in a single hospital during 2006 
but this remains unclear for both the prospective intervention and control 
group. Detailed inclusion criteria are not provided, exclusion criteria are de-
scribed in-depth and were applied equally to all groups. Although the au-
thors emphasise that the study groups were similar at baseline, they do not 
provide information regarding the severity of the underlying condition. 
Moreover, hours spent in the intensive care unit differed significantly 
(p<0.05) between the study (20 h; 5 h SD) and the control group (31 h; 21 h 
SD). In addition, patients in the intervention group spent a mean of 10 days 
(2 days SD) in hospital, whereas individuals in the control group spent a 
mean of 12 days (12 days SD) in hospital suggesting that the study group 
might have consisted of healthier individuals overall. Time periods of re-
cruitment varied between groups and this may have introduced selection 
bias. In addition, lack of blinding may have led to measurement bias. No in-
formation is provided on length of follow-up and number of patients lost to 
follow-up which could potentially have led to systematic errors, particularly 
if different between the groups. Finally, small sample sizes in both groups 
may have led to results that could have been obtained simply by chance as 
well. 
In the randomised controlled trial conducted by Karlsson M et al. (2009) [47] 
no information is provided on how randomisation to either the intervention 
or the control group was achieved. In addition, allocation concealment using 
blank envelopes is considered inadequate. Baseline characteristics were simi-
lar between the two groups. However, the small sample size may have re-
sulted in the introduction of random errors. Not only is an explanation about 
how the sample size was determined missing but the authors also state that 
due to the small sample size the study is underpowered to confirm the effi-
cacy and safety of administration of fibrinogen concentrate to CABG pa-
tients. Lack of blinding, particularly of those administering the study drug 
and assessing the outcomes, and failure to administer placebo to the control 
group could have influenced treatment decisions during surgery and subse-
quently outcomes. Neither the period of follow-up, nor the number of indi-
viduals lost to follow-up in each group is specified. As an intention-to-treat 
analysis is not mentioned at all, it remains questionable whether analysis of 
results was done adequately or not.  
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lack of blinding 
 
 
small sample sizes 
 
selection bias 
 
underpowered study 
 
lack of blinding 
 
intention-to-treat 
analysis? 
 
 
Quality of studies 
 
LBI-HTA | 2009 39 
In the second randomised placebo-controlled trial by Fenger-Eriksen et al. 
(2009) [44] the study manuscript was developed according to the CONSORT 
statement [56]. Inclusion and exclusion criteria were well defined and equally 
applied to all study participants. Randomisation was done intraoperatively 
using blank envelopes. However, it remains unclear who was in charge of 
conducting the randomisation. The authors claim that the groups were simi-
lar at baseline with regard to age, body mass index, and some laboratory pa-
rameters but no further information is provided, particularly in terms of se-
verity of the underlying condition. Considering that only two out of 20 par-
ticipants were female without knowing which group they were allocated to, 
the two arms might have been intrinsically different at the beginning of the 
trial. Blinding of the study staff was achieved by preparing and administer-
ing the study drugs by another person. No information is provided about 
who assessed the outcomes and whether this person was blinded to group as-
signment. Allocation concealment seems to have been done appropriately. 
Thresholds for transfusion of blood products, including RBC, FFP, and 
platelets were pre-defined. The period of follow-up is not stated. Although at 
first 11 participants had been allocated to the intervention group, final analy-
sis was done on ten patients only. Hence, analysis was not done as an inten-
tion-to-treat analysis. In terms of outcomes, data presented were not com-
pared between the intervention and the control group but between two dif-
ferent points in time – at baseline and before administration of fibrinogen 
concentrate or placebo. However, the authors claim that the primary out-
come MCF and maximum velocity of clot formation were significantly better 
in the fibrinogen than in the placebo group without providing supporting 
data. In addition, it remains questionable whether this difference would have 
been significant, if done as an intention-to-treat analysis. Regarding safety, 
neither adverse events nor side effects are mentioned at all. 
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In terms of safety and mortality of Haemocomplettan® P administration[45-
54], the available evidence is challenging for various reasons. The majority of 
the studies were conducted in a single institution, encompassing a consid-
erably heterogeneous patient population with multiple underlying clinical 
conditions leading to hypofibrinogenemia and bleeding, such as surgery, 
trauma, obstetric complications, liver insufficiency, haematological malig-
nancies, besides others. Most of the studies included a small number of se-
verely ill patients, ranging from six to 94 individuals. The amounts of fi-
brinogen administered vary considerably. Follow-up periods are either not 
stated, or short, or differ between studies. Most importantly, in most of the 
trials data was reviewed retrospectively which might have led to biased re-
sults. Pharmacosurveillance data, collected over 22 years by CSL Behring, 
only revealed nine cases of thrombosis overall, of which two occurred in ac-
quired fibrinogen deficiency. It remains unclear how many patients had been 
treated over this time period but the authors estimated the incidence of 
thrombosis as being 3.48 (95% CI: 1.59; 6.61) per 100,000 treatment episodes. 
However, these figures are most-likely underestimated due to under-
reporting which is very likely not only in developed European countries but 
particularly in developing countries in Asia and Africa, where there might 
not even be a system for reporting of adverse events in place. Remarkable dif-
ferences in terms of adverse events between the studies, ranging from zero to 
33%, and mortality, ranging from zero to 44%, suggest that these figures may 
also depend on the severity of the underlying condition and do not allow in-
ferences about an association with fibrinogen concentrate administration. In 
addition, because of the variety of underlying diseases included, no conclu-
sion can be drawn on a specific sub-population of patients.  
7.2 Fibrogammin® P 
We assessed the quality of the study conducted by Korte WC et al. (2009) [55] 
according to the CONSORT statement for improving the quality of reports of 
parallel-group randomised trials [56]. Although the authors describe in de-
tail inclusion and exclusion criteria for participant recruitment, they do not 
provide information about the setting, location, or time period of recruitment 
and data collection. Overall, 22 patients were enrolled in the study but no in-
formation is given about who enrolled participants and how many partici-
pants were allocated to each the study group and the placebo group. Despite 
the small sample size, randomisation was done in a blockwise manner but no 
information about the block size is provided. Hence, selection bias may have 
been introduced. Allocation concealment is not mentioned at all. Baseline 
demographics and clinical characteristics of patients are sparse with lack of a 
comparison between intervention group and control group. Blinding appears 
to have been done  
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adequately. It remains unclear who assessed the outcomes and how assessors 
had been trained. Dates and time periods of follow-up are not stated. Al-
though the surrogate endpoint MCF was significantly better in the interven-
tion than in the control group, no differences could be observed in patient-
relevant endpoints, such as transfusion requirements or length of surgery, 
most likely because the study was underpowered to detect such differences. 
Causes of death are poorly reported with stating the cause of death for one 
out of six patients only. The generalisability of the study results is question-
able because of the high-risk population undergoing a variety of surgical pro-
cedures.  Overall, due to major flaws in the quality of the study, the possible 
introduction of bias cannot be excluded jeopardising both the internal and 
external validity of study results.  
7.3 ROTEM® rotational thrombelastometry 
versus standard laboratory hemostasis 
tests 
We assessed the methodological quality of the studies [32, 35, 36] according 
to the STARD statement for the reporting of studies of diagnostic accuracy 
[57, 58].  
In the study by Coakley M et al. (2006) [32] selection bias could have been in-
troduced because important information on detailed inclusion as well as ex-
clusion criteria is missing and it remains unclear whether a consecutive se-
ries of patients was recruited or not. Baseline characteristics are sparse and 
are confined to the Child’s classification of the severity of liver cirrhosis. An-
other possible source of bias in this trial is measurement bias because the 
tests were performed at different points in time. Furthermore, information 
about the persons conducting the tests is lacking, particularly about their ex-
pertise and whether they were blinded or not. In addition, the authors do not 
provide information on test accuracy, namely sensitivity, specificity, positive 
predictive value and negative predictive value of ROTEM® FIBTEM.  
In the study by Rugeri L et al. (2006) [36] patients were enrolled consecutively 
into the study. Characteristics of the participants at the beginning of the trial 
are not stated. No information is provided on who executed the coagulation 
tests and whether this person was blinded to the results of the respective 
other test. The authors provide detailed information on the test accuracy. 
Although a consecutive series of women were enrolled into the intervention 
group in the study by Huissoud C et al. (2009) [35],  selection bias may have 
arisen by comparing a prospective intervention group and a historical control 
group because participants were selected at different points in time. Baseline 
characteristics of the two study groups are sparse and include maternal age 
and term of pregnancy only. The introduction of measurement bias may have 
been possible because measurement of  ROTEM® values was conducted by 
three clinicians. The authors provide in-depth information on the test accu-
racy. 
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7.4 Transfusion requirements and costs 
before/after implementation of 
ROTEM® rotational thrombelastometry 
The two studies identified [40, 41] were both conducted in a single institu-
tion and solely focused on patients undergoing cardiosurgical procedures.  
Anderson et al. (2006) [40] showed that although the number of patients 
transfused as well as the number of units of blood products substituted de-
creased after ROTEM® implementation, patient-relevant outcomes, includ-
ing discharge haemoglobin (Hb), length of stay in intensive care unit (ICU) 
and in hospital, and surgical re-exploration for bleeding, were not affected.  
Spalding GJ et al. (2007) [41] concluded that ROTEM® implementation de-
creased monthly costs for most blood products, except for fibrinogen, for 
which monthly costs increased almost four-fold. Therefore, it can only be 
said that ROTEM® implementation was a cost-effective strategy in these two 
specific settings but no conclusions can be drawn on other sub-populations of 
patients. Nevertheless, patient-relevant outcomes should be given priority 
over cost-reduction strategies and benefits should be carefully weighed 
against possible harms.  
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8 Discussion 
Haemocomplettan® P and Fibrogammin® P have been licensed in Austria 
since 1994 and 2000, respectively, although there is a lack of studies assessing 
the efficacy and safety of these drugs. In this systematic review we identified 
only sparse evidence, mainly from clinical trials in highly selected individu-
als, that patients may benefit from substitution of fibrinogen and factor XIII 
in certain circumstances. However, important questions regarding evidence-
based substitution of fibrinogen and factor XIII remain unclear: 
What is the threshold for substitution of fibrinogen? 
In all clinical trials assessed, fibrinogen was substituted regardless of fibrino-
gen plasma levels [44-47]. Therefore, we were not able to identify cut-off val-
ues for administration of fibrinogen, i.e. certain plasma levels at which sub-
stitution of fibrinogen would be indicated.  
Acquired hypofibrinogenemia frequently occurs due to impaired synthesis, 
increased loss, or increased consumption of fibrinogen for various reasons. In 
massive haemorrhage the substitution of crystalloids and colloids lead to the 
development of dilutional coagulopathy with fibrinogen being the first clot-
ting factor to reach a critical level [5, 6]. This critical level is discussed con-
troversially. Recent guidelines from Great Britain, Canada, Germany and 
from a European Critical Care Expert Group suggest empirically set thresh-
olds of less than 1 g/L for fibrinogen substitution [6-10]. The German Medi-
cal Assciation sets an additional threshold at less than 1.5 g/L in severe 
bleeding [10]. Only the Austrian ÖGARI guidelines for trauma-related mas-
sive bleeding propose a cut-off of less than 1.5 to 2 g/L: However, the higher 
the cut-off level, the more patients will be eligible for fibrinogen substitution 
and the more fibrinogen concentrate will be consumed, increasing costs. 
Overall, for none of the empirically defined thresholds there is any evidence 
for the “appropriate” fibrinogen substitution in any patient population.  
Which amount of fibrinogen needs to be substituted? 
In the studies identified, the total amount of fibrinogen administered varied 
considerably between the trials, ranging from about 2 to 8 g per patient. The 
amount of fibrinogen substituted may depend upon the underlying clinical 
condition and the magnitude of blood loss. Therefore, the variability in fi-
brinogen dosage may have been associated with the heterogeneous patient 
populations assessed. However, there is lack of evidence both proving the ef-
fect-size to be dose-dependent and providing maximum dosage cut-offs. 
There is not even a reasoning provided for the different dosages. 
In two of the four efficacy studies of Haemocomplettan® P[45, 46] MCF was 
assessed by ROTEM® FIBTEM to guide fibrinogen transfusion. The ration-
ale behind measuring MCF was to draw conclusions on intraoperative fi-
brinogen plasma levels. However, MCF values were chosen arbitrarily. In the 
study by Karlsson et al. (2009) [47] all patients in the intervention group re-
ceived 2 g of fibrinogen, regardless of plasma fibrinogen levels or ROTEM® 
values. In the remaining study by Fenger-Eriksen et al (2009) [44] fibrinogen 
concentrate was administered according to body weight to all patients in the 
intervention group, regardless of plasma fibrinogen levels or ROTEM® val-
ues.  
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As for the substitution of other coagulation factors, such as factors VIII or IX 
in haemophilia, or the prothrombin time in prothrombin-complex therapy, 
dosing of fibrinogen or factor XIII substitution should be guided by plasma 
levels and recovery. The gold standard for fibrinogen measurement is the 
Clauss assay, ROTEM® has been proven not to be effective for a reliable es-
timation of fibrinogen activity (see below).  
How accurate is ROTEM® FIBTEM in predicting the need for fibrinogen 
transfusion? 
ROTEM® rotational thrombelastometry seems to have some advantages over 
conventional laboratory hemostasis tests, particularly in the setting of mas-
sive bleeding, because it may be performed on-site and more quickly than the 
Clauss assay.  
We identified two studies, providing information about the test accuracy of 
ROTEM® FIBTEM in estimating fibrinogen plasma levels by employing 
various FIBTEM values [35, 36]. Although the sensitivity, specificity, and 
NPV of ROTEM® FIBTEM were good or at least fair, the PPV only ranged 
between 13% and 55% with wide 95% CI for different FIBTEM test results. 
Therefore, only a small percentage of positive FIBTEM results - correspond-
ing to a Clauss fibrinogen level <1 g/L - truly was in accordance with a fi-
brinogen concentration of less than 1 g/L. 
In the study by Rugeri L et al. (2006) [36] ROTEM® FIBTEM showed a sensi-
tivity of 91% with a wide 95% CI, ranging from 72% to 93%, indicating that 
91% of patients with a CA10-FIBTEM result of 5mm truly had a fibrinogen 
level <1 g/L. The specificity of 85% (95%CI: 84; 86%) suggests that 85% of 
individuals with a CA10-FIBTEM result of 5mm truly did not have a fibrino-
gen level of <1 g/L. Although the test had a high NPV of 99% (95% CI: 97; 
100%), indicating the proportion of tests with a negative test result which 
truly did not translate into a fibrinogen level of <1 g/L, the PPV was only 
55% with a wide 95% CI ranging from 45% to 60%. Therefore, in only 55% of 
positive test results the fibrinogen level truly was <1 g/L. Hence, it remains 
questionable whether ROTEM® FIBTEM is an adequate test in the setting of 
haemorrhage in trauma patients because it may lead to unnecessary substitu-
tion of fibrinogen and transfusion of blood products. 
Although ROTEM® FIBTEM showed a sensitivity of 100% in the study by 
Huissoud C et al. (2009) [35], the specificity only ranged from 84% to 88% 
with a wide 95% CI between 75% and 97%. Moreover, the NPV was 100% but 
the PPV decreased steadily from 50/46% in CA5-/CA15-FIBTEM 6/8mm – ac-
cording to fibrinogen levels of <2 g/l - to only 13/14% in CA5-/CA15-FIBTEM 
4/5mm – corresponding to fibrinogen levels of <1 g/L. In addition, the 95% 
CI of PPV in all cut-offs were wide. Hence, with decreasing fibrinogen levels, 
the PPV of ROTEM® FIBTEM CA5/CA15 declined as well, indicating that in 
the 37 women who experienced PPH, the prevalence of fibrinogen levels be-
low 2 g/L was low and decreased with declining fibrinogen levels. The lower 
the fibrinogen level in PPH falls, the smaller the proportion of women with a 
CA5/CA15-FIBTEM result indicating a fibrinogen level of <1/1.5/2 g/L, who 
are correctly diagnosed. Hence, those parameters may lead to fibrinogen sub-
stitution in patients who truly would not be in need for it. Using ROTEM® 
FIBTEM for guiding fibrinogen substitution leads to fibrinogen transfusion 
more often than would be required and may increase the rate of adverse 
events, such as thrombembolic complications.  
sensitivity, specificity, 
NPV were good or fair 
but PPV was poor - 13 to 
55% 
sensitivity 91%, 
specificity 85%, NPV 
99%, PPV 55%   
sensitivity 100%, 
specificity 84 to 88%, 
NPV 100%, PPV 13% to 
50% 
Discussion 
 
LBI-HTA | 2009 45 
Although two further studies [40, 41] suggested that the implementation of 
ROTEM® led to a reduction in the transfusion of blood products, such as 
RBC, FFP, and platelets, as well as a decrease in monthly costs for blood 
products, no differences in patient-relevant outcomes were observed. On the 
one hand, this finding may be in favour of ROTEM®, indicating that al-
though patients received less blood products after ROTEM® implementation, 
the discharge Hb remained the same. On the other hand, it may suggest that 
the use of ROTEM® did neither shorten length of stay in ICU or hospital, 
nor diminish the need for surgical re-exploration. Therefore, benefits should 
be weighed carefully against possible harms due to increased fibrinogen sub-
stitution.  
What is the evidence regarding adverse events and mortality of Haemo-
complettan® P? 
We discovered pharmacosurveillance data provided by CSL Behring [48] 
indicating nine adverse events over a period of 22 years, only two of which 
occurred in acquired hypofibrinogenemia. However, in the remaining studies 
identified [45-47, 49-54], the available evidence both regarding adverse 
events and mortality is conflicting, possibly due to small sample sizes, het-
erogeneous patient populations, varying dosages of fibrinogen administered, 
and mainly retrospective comparisons. In addition, causes of adverse events 
and death are often not stated and might have been influenced by the under-
lying clinical condition in these severely ill patients. 
What is the evidence for substitution of Fibrogammin® P? 
The administration of Fibrogammin® P improved MCF – a surrogate pa-
rameter – in a small group of individuals at high-risk of intraoperative bleed-
ing but no differences were observed in patient-relevant outcomes, such as 
transfusion of blood products and length of surgery, most likely because the 
study was underpowered to detect such differences. Because of the specific 
sub-population assessed and the lack of evaluating patient-relevant outcomes, 
no conclusion can be drawn about the efficacy and safety of Fibrogammin® P.  
Is there evidence for the combined administration of fibrinogen and fac-
tor XIII? 
As no studies could be found regarding the combined administration of 
Haemocomplettan® P and Fibrogammin® P in patients with acquired fi-
brinogen deficiency, such as severe haemorrhage, there is no evidence at all 
for this approach.  
Are there evidence based guidelines regarding fibrinogen and factor XIII 
substitution in Austria? 
Overall, there is a need for evidence-based transfusion guidelines in order to 
control both the substitution of fibrinogen and factor XIII. In Austria guide-
lines regarding the coagulation management in trauma-related massive 
bleeding have been published by the Task Force for Coagulation of the 
ÖGARI [11]. In additition, in one University Hospital in Austria, internal 
guidelines for the administration of fibrinogen concentrate have been devel-
oped by two authors of the ÖGARI guidelines [23]. According to these 
guidelines, Haemocomplettan® P might  
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be substituted in massive haemorrhage as well as preventively in patients at 
high risk of bleeding. However, the recommended initial dose is almost twice 
the dose outlined in the manufacturer’s summary of product characteristics. 
In addition, either the ROTEM® FIBTEM CA10 should be determined prior 
to fibrinogen substitution and should be less than 7mm, or the MCF should 
be less than 10 to 12mm, or the fibrinogen level as determined by Clauss as-
say should be less than 1.5 to 2 g/L. However, there is no underlying evi-
dence for these recommendations and it appears that they are based on per-
sonal expertise of one group of anesthesists emphasising the urgent need for 
evidence based, national transfusion guidelines in Austria. 
A number of questions regarding the substitution of fibrinogen and fac-
tor XIII, however, remain unclear: 
 Is there a score assessing the necessity of fibrinogen or factor 
XIII substitution?  
The development and implementation of a scoring tool in order to identify 
patients who will benefit from fibrinogen replacement would be useful. In 
addition, this would be helpful in achieving both a scientifically and eco-
nomically justifiable use of this therapy. A score should include patient-
specific and disease-specific parameters, laboratory values, and parameters 
estimating the bleeding risk. Such a scoring system would need to be vali-
dated in appropriately designed studies. 
 What influence does the dynamic of the plasma fibrinogen or 
factor XIII levels have?  
To the best of our knowledge, to date, no study has investigated the dynamic 
of fibrinogen or factor XIII plasma levels and its consequence for fibrinogen 
or factor XIII replacement in target patients. The clinical course of the un-
derlying disorder could best be monitored by measuring the increase or de-
crease of fibrinogen or factor XIII plasma levels and by putting these values 
in context with other laboratory or clinical parameters.   
 What is the appropriate dosage of fibrinogen or factor XIII con-
centrate in specific clinical settings, which are adequate inter-
vals of administration, and how long is the appropriate duration 
of treatment?  
Although the total amount of fibrinogen replacement was within a narrow 
range (see above), the available studies did not address the necessary number 
of infusions, the intervals between the infusions, and the appropriate dura-
tion of therapy. Furthermore, the target population was of considerable het-
erogeneity. Hence, in some patients a single infusion may be sufficient, 
whereas in others several days of therapy with two or three infusions daily 
may be adequate.   
 Which would be adequate study designs to answer these ques-
tions?  
Due to the heterogeneity of the possible target population the design of a ran-
domized controlled trial with sufficient statistical power is cumbersome. The 
definition of inclusion and exclusion criteria, trigger events for substitution 
of fibrinogen or factor XIII, and clinical (amount of bleeding) as well as sur-
rogate outcome parameters (Clauss fibrinogen level or ROTEM® values) all 
have a great impact on the message and clinical relevance of such a trial.  
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9 Conclusion 
In conclusion, almost all studies identified in our systematic review were 
funded by CSL Behring GmbH, Marburg, Germany - the manufacturers of 
Haemocomplettan® P and Fibrogammin® P. 
The results of these trials are not generalisable due to highly selected and 
very heterogeneous patient populations. In addition, only studies assessing 
the intraoperative administration of fibrinogen concentrate have been pub-
lished. Therefore, the use outside the operating theatre is not supported by 
any evidence. There is lack of evidence about the efficacy of Haemocomplet-
tan® P because fibrinogen concentrate administration was almost always 
combined with substitution of FFP. There is no evidence for definite substi-
tution triggers for fibrinogen, such as fibrinogen plasma levels or certain 
amounts of blood loss. Furthermore, there are no certain cut-off levels for 
ROTEM guided transfusion of fibrinogen. However, once fibrinogen substi-
tution has been decided on, the amount of fibrinogen concentrate that needs 
to be transfused remains unclear. 
Concerning Fibrogammin® P, there is lack of evidence about the use of this 
drug as we only identified one trial comprising a highly selected patient 
population.  
The combined administration of Haemocomplettan® P and Fibrogammin® P 
is not supported by any evidence. 
No evidence could be identified supporting the recommendations outlined in 
existing guidelines, namely internal guidelines in one University Hospital 
and ÖGARI guidelines, particularly regarding the indications, cut-off values, 
and dosages for fibrinogen substitution. 
Overall, given the lack of evidence regarding Haemocomplettan® P and Fi-
brogammin® P on the one hand and their steadily increasing consumption 
within Austrian hospitals on the other hand, prospective, (randomised) con-
trolled trials of good quality and sufficient size, assessing patient-relevant 
outcomes, are urgently requested to investigate the efficacy and safety of 
these two drugs in acquired hypofibrinogenemia. In the meantime, it will be 
of utmost importance to demand thorough documentation of the use of 
Haemocomplettan® P and Fibrogammin® P, including recording of the set-
ting, patient population,  dosages, cut-off values, follow-up periods, adverse 
events and side-effects. In addition, the development of evidence based, na-
tional Austrian transfusion guidelines will be inevitable. 
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